

1 SUPERIOR COURT OF THE STATE OF CALIFORNIA 2 COUNTY OF SAN FRANCISCO 3 4 DEWAYNE JOHNSON, 5 Plaintiff, 6 Case No. CGC-16-550128 vs. 7 MONSANTO COMPANY, et al., 8 Defendants. / 9 10 11 Proceedings held on Monday, July 16, 2018, 12 Volume 10, Afternoon Session, before the Honorable 13 14 Suzanne R. Bolanos, at 1:21 p.m. 15 16 17 18 19 20 21 REPORTED BY: 22 LESLIE ROCKWOOD ROSAS, RPR, CSR 3462 23 Job No. 2965312B 24 25 Pages 2280 - 2422


```
APPEARANCES:
 1
 2
 3 FOR THE PLAINTIFF:
 4
        R. BRENT WISNER, ESQ.
 5
        BAUM, HEDLUND, ARISTEI, GOLDMAN PC
 6
        12100 Wilshire Boulevard, Suite 950
 7
        Los Angeles, California 90025
 8
        310-207-3233
9
10
        DAVID DICKENS, ESQ.
        THE MILLER FIRM, LLC
11
12
       108 Railroad Avenue
13
       Orange, Virginia 22960
        540-672-4224
14
15
16 FOR THE DEFENDANT:
17
        SANDRA A. EDWARDS, ESQ.
       FARELLA BRAUN + MARTEL LLP
18
19
        235 Montgomery Street
20
        San Francisco, California 94104
21
       415-954-4400
22
23
24
25
```


```
APPEARANCES (Continued):
 1
 2
 3 FOR THE DEFENDANT:
 4
        GEORGE C. LOMBARDI, ESQ.
 5
        JAMES M. HILMERT, ESQ.
 6
        WINSTON & STRAWN LLP
 7
        35 West Wacker Drive
 8
        Chicago, Illinois 60601
 9
        312-558-5969
10
11
        KIRBY T. GRIFFIS, ESQ.
12
        HOLLINGSWORTH LLP
13
        1350 I Street, N.W.
        Washington, D.C. 20005
14
15
        202-898-5800
16
17
18
19
20
21
22
23
24
25
```


1		INDEX OF PR	OCEEDING	GS	
2					
3	WITNESS	DIRECT	CROSS	REDIRECT	RECROSS
4	CHRISTOPHER JUDE PORTIER		2296	2385	
5	FORTIER		2290	2303	
6					
7					
8		EXHIBITS A	DMITTED		
9		(None	•)		
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21					
22					
23					
24					
25					
































	1	
	1	CROSS-EXAMINATION (Continued)
	2	BY MR. GRIFFIS:
	3	Q. Good afternoon, sir.
	4	A. Good afternoon.
13:38:52	5	MR. GRIFFIS: Could we briefly have back up the
	6	slide that was on when we adjourned.
	7	Q. So we've been through the tables in the 2016 OPP $% \mathcal{O}_{\mathcal{O}}$
	8	report on this, and I just before we move on, I just
	9	want to call your attention to the header, which is
13:39:10	10	"Glyphosate Studies Considered By EPA," because we're
	11	about to look at something slightly different from that.
	12	So take a look, again, at the Exhibit 2481. I
	13	believe that's in Regulatory Binder 2. That will, again,
	14	be the OPP 2016 report.
13:39:34	15	A. Okay.
	16	Q. All right. And we looked at Tables 5.1 and 5.7.
	17	I now want to go to Tables F.1 and subsequent, which
	18	starts at page 214.
	19	A. Okay.
13:40:08	20	Q. All right. So Table F1, starting on page 214,
	21	is an <i>in vitro</i> a series of again, it's a table of
	22	studies reviewed by EPA.
	23	MR. GRIFFIS: You can take that down for the
	24	moment, Armando. Thank you.
13:40:25	25	Q. In the category in vitro tests for gene

	1	mutations in bacteria glyphosate formulations; correct?
	2	A. That's what it says.
	3	Q. So glyphosate formulations would be the
	4	glyphosate and the surfactant and the other ingredients;
13:40:46	5	right?
	6	A. Correct.
	7	Q. Okay. And there are a bunch of studies
	8	mentioned there. We're starting on 214. We go through
	9	page 218 in the category in vitro tests for gene
13:41:01	10	mutations and bacteria; correct?
	11	A. Correct.
	12	Q. All right. And then table F2, in vitro tests
	13	for chromosome damage in mammalian cells, and that's
	14	again glyphosate formulations; correct?
13:41:15	15	A. Correct.
	16	Q. F3. We're now on page 220. In vivo, living
	17	animals, tests for chromosomal aberrations in mammals,
	18	glyphosate formulations; correct?
	19	A. Correct.
13:41:29	20	Q. Table F4 on page 221. In vivo tests for
	21	micronuclei induction in mammals, glyphosate
	22	formulations; correct?
	23	A. Correct.
	24	Q. That runs through 224. And then on table F5 on
13 : 41 : 48	25	page 225, other assays for detecting DNA damage,

	1	glyphosate formulations; correct?
	2	A. Correct.
	3	Q. Okay. Now turn in your blue binder to tab 3182.
	4	Sorry. Are you there?
13:42:13	5	A. Yes, I am.
	6	Q. We have another chart much like the previous
	7	chart, but this one is labeled "Formulated Product
	8	Studies Considered by EPA." Correct?
	9	A. That's what it's labeled, yes.
13:42:27	10	Q. And then we have the categories I just discussed
	11	starting with in vivo tests for gene mutation bacteria,
	12	from table F1, and running through other assays for
	13	detecting DNA damage?
	14	A. Correct.
13:42:39	15	Q. Which corresponds to F5?
	16	MR. GRIFFIS: I ask for permission to publish
	17	this table, your Honor.
	18	THE COURT: Any objections?
	19	MR. WISNER: With the same proviso of accuracy.
13:42:49	20	MR. GRIFFIS: Oh, yes.
	21	Q. And again, you're not vouching for this one any
	22	more than you vouched for the last one; right, sir?
	23	A. Correct.
	24	Q. Okay. So let's go back to the first row, the
13:43:06	25	blue row. This is in vitro test for gene mutation in

	1	bacteria, corresponding to table F1. And F1 again starts
	2	on 214.
	3	A. So if I might point out, the title of this is
	4	wrong, just to be clear. These are <i>in vitro</i> tests for
13:43:35	5	gene reverse mutations in bacteria, and it actually does
	6	matter.
	7	Q. Okay. EPA got it wrong in its label, too;
	8	right?
	9	A. Yes, correct.
13:43:45	10	Q. Okay. Please explain the difference between
	11	gene mutations and gene reverse mutation, given this kind
	12	of test.
	13	A. A gene mutation is when you change a normal gene
	14	into something else. Here there's there's a gene
13:43:58	15	which is stopping growth. It's a single gene, and when
	16	the DNA damage comes in, it's known that the repair
	17	machinery in that cell will reverse that mutation. It
	18	will take it out and clean it off, and the cell will then
	19	go back into replicating and build the colonies. And so
13:44:17	20	it's a reverse mutation.
	21	Q. And this is the special test assay you've
	22	described to the jury before.
	23	A. Correct.
	24	Q. There's a custom modified cell with a gene in it
13:44:29	25	that keeps it from doing what it would normally do, grow,

	1	and this is a test of whether a substance knocks that
	2	gene out, causing it to grow. And that's a nice elegant
	3	test because if it does, you can see it. It starts
	4	growing, you can look at your petri dishes; right?
13:44:46	5	A. It's cheap, it's fast, and it's easy to
	6	quantify.
	7	Q. So column 1 or row 1, the in vitro test for gene
	8	reverse mutation in bacteria corresponding to table F1,
	9	those are all negative as reported by EPA, except for
13:45:07	10	one, which is reported as partially negative, partially
	11	equivocal; correct?
	12	A. That is correct.
	13	Q. Table F or sorry, row F2, in vitro tests for
	14	chromosome damage in mammals. That's the red one.
13:45:24	15	That's just two. One is reported as negative and one is
	16	reported as positive; correct?
	17	A. That's what it says in the table.
	18	Q. Table F3, the orange or sorry, the orange row
	19	corresponding the tables F3 and F4, we have a positive,
13:45:48	20	negative, positive in F3; correct?
	21	A. Correct. That's the <i>in vitro</i> test for
	22	chromosome aberrations in males.
	23	Q. In vivo; right? And then for micronuclei
	24	induction, we have a positive and then a long string of
13:46:06	25	negatives; correct?

	1	A. There's a footnote on one of them I don't I
	2	can't seem to locate, but yes, they're all listed as
	3	negative.
	4	Q. Okay. And then the last row, the purple, other
13:46:30	5	assays for detecting DNA damage, we have one, two, three,
	6	four, five, six. And those are all reported as positive
	7	one way or another. One of them says induced DNA
	8	migration at greater than 22 MG. I assume that's
	9	positive in some fashion; correct?
13:47:01	10	A. Excuse me. I count eight, and probably that
	11	they are intending that to mean positive.
	12	Q. Okay. And several are sister chromatinic
	13	changes, the same kind of tests we discussed last time?
	14	A. Three of the eight.
13:47:21	15	Q. Okay, sir. And again, I take it that you would
	16	not know without getting out the IARC Monograph and
	17	comparing item by item which of these IARC did not
	18	consider; is that fair?
	19	A. That's that's probably true. I think
13:47:39	20	everything here that's labeled with a name and a number
	21	that is in the public's literature, IARC will have
	22	covered. But some of these in this last section for
	23	sure. But in some of these early ones that are coming
	24	from regulatory studies, I doubt if they would have
13 : 47 : 57	25	looked at it.

	1	Q. All right.
	2	MR. GRIFFIS: Take the slide down, please.
	3	Q. Now EPA also looked at some of the human studies
	4	on the issue of mechanism that you relied on for your
13:48:17	5	opinion that glyphosate is genotoxic, like the Bolognesi
	6	and Paz-y-Miño studies, and those are the ones that
	7	involved aerial spraying of glyphosate formulations in
	8	Ecuador; correct?
	9	A. Correct. EPA looked at those.
13:48:31	10	Q. All right. And EPA classified them of being of
	11	poor design and unworthy of further analysis; correct?
	12	A. Again, we'd have to look at the wording they
	13	used.
	14	Q. Okay. Do you remember that?
13:48:44	15	A. I remember they didn't think highly of the
	16	studies.
	17	Q. You think more highly of them than EPA does; is
	18	that fair?
	19	A. I think they contribute to the information. I
13:48:53	20	definitely would not exclude them.
	21	Q. I'm sorry?
	22	A. I definitely would not exclude them.
	23	Q. Okay.
	24	A. If the language you just used for EPA is
13:49:02	25	correct, then they were basically excluding it from any

1 further evaluation.

	<u></u>	rurther evaluation.
	2	Q. When you say you wouldn't exclude them, the EPA
	3	did exclude them. What how much what words would
	4	you use to describe how much weight they deserve?
13:49:19	5	A. The Bolognesi deserves significant weight. The
	6	Paz-y-Miño's probably less because they're more what's
	7	called an ecological study where you have two communities
	8	that are different from each other and you're attributing
	9	the difference to the spraying, whereas there could be
13:49:35	10	other things, versus the Bolognesi, where each person is
	11	their own control. And so you test before and test
	12	after. That warrants much more weight.
	13	Q. Okay. Would you turn to page 2099. I think
	14	this is in your blue binder, the Bolognesi study.
13:49:57	15	A. You mean tab 2099.
	16	Q. Tab 2099. Apparently I'm wrong about that.
	17	The I'm sorry, sir, not the blue binder. It's in the
	18	binder that's labelled "Trial Cost Number 2."
	19	A. And what was that number again?
13:50:24	20	Q. 2099.
	21	A. Okay.
	22	Q. And that's the Bolognesi study; correct?
	23	A. That is the Bolognesi study.
	24	MR. GRIFFIS: Okay. Ask permission to publish
13 : 50:48	25	the Bolognesi study on the screen, your Honor.

	1	MR. WISNER: No objection.
	2	THE COURT: All right. Very well. You may
	3	proceed.
	4	Q. BY MR. GRIFFIS: So let's go first to well,
13:51:00	5	first of all, we're going to see a term, an abbreviation
	6	BNMN. What is BNMN in this study?
	7	A. Bi-nuclei, micronuclei.
	8	Q. That's what they were looking for, the endpoint
	9	they were looking at?
13:51:15	10	A. They looked at several endpoints, but that's the
	11	one they presented in greater detail.
	12	Q. Okay. Let's go to page 995, the last page of
	13	text in the study.
	14	A. Okay.
13:51:30	15	Q. That would two more pages, please. 995. That's
	16	it.
	17	And first I'd like to start in the left-hand
	18	column. If we could blow this up because it's real
	19	small, just highlighting isn't going to work.
13:51:50	20	Evidence indicates. Thank you.
	21	Dr. Bolognesi wrote: "Evidence indicates that
	22	the genotoxic risk potentially associated with exposure
	23	to glyphosate in the areas where the herbicide is applied
	24	for eradication of cocoa and poppy is of low biological
13:52:10	25	relevance."

		
	1	Correct?
	2	A. Hold on for a second, please, while I read it.
	3	That's what it says, yes.
	4	Q. Over on the next column, the right-hand column,
13:52:44	5	based on.
	6	"Based on the applicable Bradford-Hill
	7	guidelines." These are the guidelines that you used
	8	right at the end of your direct examination; correct?
	9	A. Yes.
13:52:58	10	Q. It's a fairly standard set of criteria to
	11	organize causation conclusions; right?
	12	A. Correct.
	13	Q. Okay. "Based on the applicable Bradford-Hill
	14	guidelines, it is not possible to assign causality to the
13:53:13	15	increases in frequency of BNMN observed in our study."
	16	Right?
	17	A. That's what it says.
	18	Q. And then in the last paragraph, starting "the
	19	smaller number of subjects." Well, they say first
13:53:29	20	further studies are needed. Then the smaller number of
	21	subjects recruited in this study and the small amount of
	22	information about the exposure precluded any conclusions;
	23	right?
	24	A. That's what it says.
13:53:40	25	Q. On page 994, the previous page, in the

	1	right-hand column and I'm on the second paragraph from
	2	the end, first sentence. That's it.
	3	There was no significant association between
	4	self-reported direct contact with the eradication sprays
13:54:04	5	and frequency of BNMN; correct?
	6	A. That's what it says.
	7	Q. Okay. Now with regard to the Paz-y-Miño study,
	8	there were two, one in 2007 and one in 2011; correct?
	9	A. Correct.
13:54:30	10	Q. Let's find them in your binder. It's going to
	11	be the same binder. 2883 for the 2007 one. 2882 for the
	12	2011 one. Can you just identify that I got that right?
	13	A. 288
	14	Q. 2883. I don't have them in order. 2883 is the
13:54:55	15	2007, and then 2882 is the 2011.
	16	A. Yeah, that appears to be the case.
	17	Q. Okay. So let's go to 2883, the first study the
	18	2007 one.
	19	MR. GRIFFIS: And permission to publish this to
13:55:11	20	the jury, your Honor.
	21	THE COURT: Any objection?
	22	MR. WISNER: No objection, your Honor.
	23	THE COURT: All right. Very well. You may
	24	proceed.
13:55:18	25	Q. BY MR. GRIFFIS: Go to page 459 so we can look

	1	at their last paragraph's conclusion.
	2	A. Okay.
	3	Q. And the last paragraph before they get to the
	4	acknowledgements says: "Our findings suggest the
13:55:34	5	existence of a genotoxicity risk for glyphosate exposure
	6	in the formulation used during the aerial spraying and
	7	indicate the need for further studies on individuals
	8	exposed to glyphosate to determine its possible influence
	9	on genetic material."
13:55:49	10	Correct?
	11	A. That is what it says.
	12	Q. And they went on and did a larger study, which
	13	is the Paz-y-Miño 2011 study; correct?
	14	A. It's slightly bigger, yes.
13:56:03	15	Q. Okay. 2882 is that study.
	16	MR. GRIFFIS: Permission to publish it.
	17	THE COURT: Any objection?
	18	MR. WISNER: No objection.
	19	THE COURT: Very well.
13:56:09	20	Q. BY MR. GRIFFIS: In the abstract, I'd like to
	21	just focus on the "in conclusion" sentence at the end.
	22	Well, two sentences.
	23	"In conclusion, the study population did not
	24	present significant chromosomal and DNA alterations. The
13:56:27	25	most important social impact was fear. We recommend

1 future prospective studies to assess the communities." 2 Correct? 3 That's what it says. Α. Q. On the subject of fear, of course, what we're 4 13:56:40 5 talking about is military planes suddenly appearing and 6 spraying people's villages and fields as part of a cocoa 7 eradication project; right? MR. WISNER: Objection. Speculation. 8 9 THE COURT: Overruled. He may answer, if he 13:56:53 10 knows. 11 THE WITNESS: I would just be speculating. Ι 12 have no idea. 13 Q. BY MR. GRIFFIS: Okay, sir. It's not explained in here. 14 Α. I will point out this study looked at DNA damage 13:56:58 15 16 much later after the spraying than did the other study, 17 which makes this study of less value because the DNA 18 damage will disappear over time. Q. On page 50, sir, left-hand column, very last 19 13:57:18 20 line. 21 Α. I'm there. 22 Q. And we're going to have to just do a little 23 graphics move to get up to the top of the next column. 24 "Regarding our study, we have obtained results 25 showing no chromosomal alterations in the analyzed 13:57:38

individuals." 1 2 Right? 3 A. Correct. Q. And it goes on to talk about the socially and 4 13:57:48 5 psychologically negative impact of the spraying on the 6 community; right, sir? 7 A. Correct. Q. Now, another genotoxicity article, it wasn't 8 9 itself a study, but it was an article that you discussed 13:58:05 10 in your direct examination was a metaanalysis by 11 Dr. Ghisi; correct? 12 A. Correct. 13 Q. And you put up a graphic showing some 14 comparisons of different exposure methods in that study; 15 correct? For example, there was one that had spray over 13:58:20 16 here and the oral exposure was right around the no effect 17 line; right? A. Correct. 18 Q. Okay. Spray was much farther to the right, and 19 13:58:34 20 Mr. Wisner asked you is spraying greater than oral, and 21 you confirmed that's what the chart showed; right? 22 A. Correct. 23 Q. And you said you thought that that was the 24 spray, spray finding, you thought that was the human 25 population, and you said the Bolognesi study; right? 13:58:48

	1	A. That was my guess.
	2	Q. Meaning the one where humans were sprayed in
	3	Ecuador that we just talked about.
	4	Let's find Ghisi. That is 2190. It's in the
13:59:07	5	blue binder, I believe.
	6	A. That is the study.
	7	Q. Okay.
	8	MR. GRIFFIS: Permission to publish.
	9	THE COURT: Any objection?
13:59:26	10	MR. WISNER: No objection, your Honor.
	11	THE COURT: Very well. You may proceed.
	12	Q. BY MR. GRIFFIS: That's the front page. If we
	13	go into page 46 where table 1 begins.
	14	A. Yes.
13:59:40	15	MR. GRIFFIS: Would you put that up.
	16	Q. Okay. So table 1, we'll look at in detail, but
	17	I know it's a long table, and these are each these
	18	aren't individual studies that were included in the
	19	metaanalysis. They're individual tests; right?
13:59:54	20	A. That is correct. There's individual doses and
	21	tests.
	22	Q. So we have two different doses that are one and
	23	two, that correspond to one study, two doses that
	24	correspond to one study, et cetera. Sometimes one dose
14:00:09	25	is one study; sometimes there are multiple doses for a

	1	study; right?
	2	A. Correct.
	3	Q. And right here we can see the route, the route
	4	of administration; correct?
14:00:20	5	A. Oh, yes.
	6	Q. Spray, oral, et cetera. So why don't you look
	7	at the whole table, and it goes on for another page, and
	8	see where we get the spray data from.
	9	A. I stand corrected.
14:00:52	10	Q. Okay. Corrected in what fashion, sir?
	11	A. The only spray data up there was crocodilian,
	12	crocodiles.
	13	Q. From the Poletta study right here, that one
	14	study?
14:01:03	15	A. Correct.
	16	Q. Would you turn to page 3187 in your binder, sir,
	17	and see if that is a true and accurate depiction of the
	18	species
	19	A. You mean tab?
14:01:12	20	Q. Tab, yes. C. latirostris, which is the species
	21	from that study.
	22	MR. WISNER: What tab?
	23	MR. GRIFFIS: The last tab, 3187.
	24	THE WITNESS: I don't I don't have a 3187 in
14:01:31	25	this book.

	1	MR. GRIFFIS: (Indicating.) It's in the blue
	2	binder, sir. There you are.
	3	THE WITNESS: It's either a crocodile or an
	4	alligator.
14:01:45	5	MR. GRIFFIS: Permission to publish 3187, your
	6	Honor.
	7	MR. WISNER: I would object. He hasn't laid the
	8	foundation that this is exactly what we're talking about.
	9	I've never seen the picture before.
14:01:55	10	Q. BY MR. GRIFFIS: It's a picture of a
	11	broad-tailed caiman, sir. Does it look close enough for
	12	government work?
	13	A. I wouldn't know.
	14	Q. Okay. It's a crocodilian species; right? If
14:02:05	15	it's not that one, it's one that looks reasonably
	16	similar?
	17	A. Crocodilian or alligator, I don't know. But if
	18	you tell me it's a caiman, it's neither. It's a caiman.
	19	Q. Take a look at the dose that was used in the
14:02:19	20	study, please. When you've found it, let us know what it
	21	is.
	22	A. It says 19,800
	23	Q. 19,800 what?
	24	A. Oh, sorry. Milligrams per liter per milligrams
14:02:52	25	per kilogram.

	1	Q. What does that mean?
	2	A. I have no idea. But that's what it says on the
	3	top, dose in.
	4	Q. Is it the biggest one in the chart?
14:03:02	5	A. Yes, it is.
	6	Q. You aren't telling the jurors that they should
	7	conclude anything from that spray finding in the Ghisi
	8	metaanalysis about the risks to human pesticide
	9	applicators from glyphosate formulations; right?
14:03:24	10	A. That is correct. I stand corrected.
	11	Q. Yes, sir. Thank you.
	12	The authors didn't perform and this is a
	13	this is a metaanalysis, not a study. They didn't perform
	14	their own assay or test or study; correct?
14:03:40	15	A. Correct.
	16	Q. And this is the first time you've seen a
	17	metaanalysis Forest plot in published genotoxicity
	18	literature; right?
	19	A. Yes.
14:03:48	20	Q. Okay. Let's pull up that Forest plot for a
	21	moment.
	22	My mind is going blank. Let's to the bottom of
	23	page 48, which is 0007. Just pull that up for a second.
	24	And we have a very disparate group of animals
14:04:21	25	and even non-animals in this; correct?

	1	A. What would constitute a non-animal?
	2	Q. Well, 93, this one that's farthest over to the
	3	right is an onion; right?
	4	A. Oh, right. I think that's the only one.
14:04:36	5	Q. Onion, and the next one is a fish and the next
	6	one is a fish.
	7	A. Yes, Fish.
	8	Q. Okay.
	9	A. All kinds of things.
14:04:47	10	Q. All kinds of things; right? And one of the
	11	things they looked for is statistically homogenous
	12	pairings; right? They did statistical analyses to see
	13	where results in different studies were statistically
	14	homogenous?
14:05:04	15	A. You're actually testing for heterogeneity, but
	16	yes.
	17	Q. All right. And if I get into detail about
	18	exactly what they did, I think
	19	A. We'd be locked up. Sorry.
14:05:14	20	Q. We'd be here a while.
	21	But one of their findings was that crocodiles
	22	and mammals form the statistically homogenous group;
	23	correct?
	24	A. You'd have to point me to where they actually
14:05:29	25	said that.

	1	Q. Okay. That's on the same page, which is page 48
	2	of the study, second column, first paragraph. The
	3	sentence starting in figure 2B.
	4	And I'm sorry, and it's not the crocodilians and
14:05:55	5	the mammals; it's the crocodilians and the mice. In
	6	figure 2B we can see the clear formation of two groups.
	7	Crocodilians are very close to mice. And then there's a
	8	fish and amphibian cluster as well; right?
	9	A. The p-value for that is .066.
	10	Q. So
	11	A. Marginally significantly different.
	12	Q. Okay.
	13	A. Now, their interpretation of that is there's
	14	nothing there. My interpretation is there's something
14:06:23	15	there.
	16	Q. Okay. Are you in your blue binder? I've lost
	17	track.
	18	A. I'm still in the blue binder.
	19	Q. 3039, this is the Tarazona article again. Are
14:06:52	20	you there?
	21	A. I'm ready.
	22	MR. GRIFFIS: Permission to publish.
	23	THE COURT: Any objection?
	24	MR. WISNER: I'm sorry, I wasn't paying
14:06:59	25	attention.

I

	1	MR. GRIFFIS: We're back at Tarazona.
	2	MR. WISNER: Oh, yeah. Go ahead.
	3	Q. BY MR. GRIFFIS: Page 12 of our Exhibit 3039,
	4	12, also the 12th page of the article. And I'd like to
14:07:14	5	go to the bottom paragraph starting "a recent
	6	metaanalysis."
	7	Dr. Tarazona is head of pesticides unit at EFSA.
	8	He wrote: "A recent metaanalysis on micronuclei
	9	frequency, Ghisi, et al., 2016, has confirmed that
14:07:39	10	positive effects are limited to intraperitoneal
	11	administration and that the response is much higher for
	12	glyphosate-based formulations than for the active
	13	substance."
	14	So remind us what an intraperitoneal
	15	administration is, please, sir.
	16	A. That's where the needle is used to insert it
	17	into the intraperitoneal cavity.
	18	Q. And one reason that that is used is because the
	19	intraperitoneal cavity is very rich in blood vessels and
14:08:09	20	takes up substances very rapidly and it also gives access
	21	to lots of organ surface; correct?
	22	A. That's one of the reasons.
	23	Q. It's obviously not something that happens to
	24	people. It only happens to experimental animals in these
14:08:21	25	kinds of studies; right?


	1	A. Yeah, I would hope. I don't think it ever
	2	happens to people.
	3	Q. "Cytotoxicity of the surfactant added to the
	4	formulation is presented as a plausible explanation,
14:08:39	5	while the cytotoxicity of glyphosate in intraperitoneal
	6	administrations at high doses is not discussed."
	7	So Dr. Tarazona is talking about the surfactant
	8	ingredient causing the cytotoxicity we were discussing
	9	earlier today, the direct irritation, the direct acute
14:08:58	10	effect on the tissues that it comes into contact with in
	11	the intraperitoneal administration; correct?
	12	A. That's what he's talking about.
	13	Q. "Significant differences are observed for males,
	14	but not for females. The general difference his report
14:09:16	15	in the comparison of mammalian and non-mammalian systems
	16	although similar responses are observed for mice and
	17	crocodilians, Ghisi, et al., 2016."
	18	Correct?
	19	A. That's what he says.
14:09:32	20	Q. Now, over on page 13, the one where we ended up
	21	here, over on the second column, first full paragraph, at
	22	the end he talks about the issue of carcinogenicity and
	23	genotoxicity testing being done on individual chemicals
	24	versus formulations; right?
14:09:58	25	A. Where? Where are we talking?

	1	Q. In fact. I'm starting with in fact.
	2	"In fact, the UN and EU guidance recommends
	3	carcinogenicity and genotoxicity studies to be conducted
	4	on individual chemicals, limiting testing of
14:10:12	5	mixtures/formulations to cases where synergistic effects
	6	are expected, United Nations, 2015."
	7	Correct?
	8	A. That's what it says.
	9	Q. And manufacturers seeking approval for a product
14:10:26	10	are required to submit carcinogenicity testing and
	11	genotoxicity testing on the so-called active ingredient
	12	by itself; correct?
	13	A. Correct.
	14	Q. You wouldn't be allowed to just submit
14:10:41	15	formulated product testing; right?
	16	A. I don't know.
	17	Q. And there may be cytotoxicity reasons that
	18	formulated product testing in whole animals wouldn't work
	19	so well; is that fair?
14:10:52	20	A. I don't know.
	21	Q. Okay. Let's go to the last page of tests.
	22	That's 18. Right-hand column. I'm sorry, the left-hand
	23	column.
	24	The first full paragraph at the bottom, starting
14:11:27	25	"in fact." And again, we're talking about genotoxicity

	1	evidence; correct?
	2	A. Starting with where, "in fact"?
	3	Q. "In fact."
	4	A. Okay. I've got it.
14 : 11 : 46	5	Q. "In fact, all oral studies, even at very high
	6	doses, are negative, and the only in vivo mammalian
	7	positive evidence was for intraperitoneal studies at very
	8	high doses in which cytotoxicity is expected. This is
	9	again linked to the consideration of secondary effects
14:12:06	10	due to severe systemic toxicity described above for the
	11	animal studies, which should be excluded for the
	12	classification of genotoxicity and carcinogenicity
	13	according to the UN GHS criteria."
	14	Did I read that right?
14:12:19	15	A. You read it right.
	16	Q. What's Union GHS criteria, please?
	17	A. Globally Harmonized System of classification and
	18	labeling of chemicals. And why they have guidelines
	19	on why you only do a single chemical versus mixtures,
14:12:47	20	I don't know. I've never read those guidelines.
	21	Q. Sir, last week we talked about a consulting
	22	contract that you signed nine days after The Lancet
	23	article was published with the Working Group 112 results;
	24	correct?
14:13:00	25	A. Correct.

	1	Q. And I would like to look now at a quote you gave
	2	to Agri-Pulse magazine. So turn to page 3021. Not page,
	3	tab 3021 in the blue binder, please.
	4	A. Okay.
14:13:19	5	Q. And that is an article in Agri-Pulse called "Oh
	6	Brother." Right?
	7	A. Yes.
	8	Q. And it's called "Oh Brother" because it's a
	9	little piece about how you and your brother, Kenneth
14:13:33	10	Portier, who is also a Ph.D. biostatistician and on the
	11	EPA science advisory panel for glyphosate, disagree about
	12	glyphosate; right?
	13	A. I'm sorry?
	14	Q. Okay.
14:13:44	15	A. I missed that last point.
	16	Q. Disagree about glyphosate.
	17	A. Who disagreed?
	18	Q. You and your brother.
	19	A. That's not what this article is about.
14:13:53	20	Q. What's it about?
	21	A. It's just about the fact that my brother's on
	22	the SAP. I don't think
	23	Q. You two do disagree about glyphosate; right?
	24	A. Not not totally. Certain things certain
14:14:09	25	pieces of data, we disagree about, correct.

	1	Q. Okay. Take a look, sir, at you gave a quote
	2	that is excerpted here. It's at the bottom of page 2,
	3	sir. I'll read it. Tell me if I get it right.
	4	"'Nobody has paid me a cent to do what I'm doing
14:15:01	5	with glyphosate,' he said," meaning you. "I have no
	6	conflict of interest whatsoever."
	7	A. That's what the article says.
	8	Q. That was October 12th, 2016; correct?
	9	A. Correct.
14:15:12	10	Q. Is it an accurate quote?
	11	A. As I pointed out to the author and to other
	12	people who have asked me that, I don't really know. It's
	13	in the interview. It's in the context of them talking
	14	about the work I do with the Environmental Defense Fund,
14:15:30	15	and I have no idea if I was answering a question about
	16	whether they were paying me to do what I'm doing or
	17	whatever. So I don't know.
	18	But with regard to the document presented here,
	19	I just don't know.
14:15:44	20	Q. Okay. Would you turn to 2300 in the blue
	21	binder.
	22	MR. WISNER: Your Honor, could we have a
	23	sidebar?
	24	THE COURT: Yes.
14:15:55	25	(Sidebar.)



	1	A. I don't have the tab.
	2	Q. You don't have 2300? It is
	3	A. These were in order; right? I have 2190 to
	4	2334.
14 : 17:46	5	Q. You may have mine (indicating). Sorry.
	6	I'll give you a moment.
	7	A. Okay.
	8	Q. All right. So this is an email from the author
	9	of the an article that we were taking about, dated
14:18:11	10	October 19, 2017, and it's addressing this issue of
	11	whether you were were or were not misquoted in the
	12	article; correct?
	13	A. Correct.
	14	Q. He quotes you and this is about halfway
14:18:23	15	through this first page, which is the body of the email.
	16	And it says he points out that you've said: "This
	17	pertains to the work I did part-time for the
	18	Environmental Defense Fund. It's conceivable the
	19	reporter got this quote out of context. I can't tell you
14:18:40	20	whether certainly I got it or not. I've been misquoted
	21	many times."
	22	And then he responds to that; correct?
	23	A. That this is what it says, yes.
	24	Q. Okay. He says: "While the quote comes after
14:18:51	25	the EDF paragraph, it also is fairly broad, as it says

	1	nobody has paid you anything to do what you were doing
	2	with glyphosate."
	3	"Concerning that the EDF graph" meaning
	4	paragraph "notes that you have done no pesticide work
14:19:06	5	for them, it seems clear to me that you are not talking
	6	about EDF, but about a hypothetical anyone else."
	7	"I looked back at my notes and you said nobody
	8	has paid me a cent in any way, shape, or form to do what
	9	I'm doing with glyphosate. I have no conflict of
14:19:21	10	interest whatsoever."
	11	"Either I conflated that without any ellipsis or
	12	my editor did, but that quote with any way, shape or form
	13	is actually more broad, it seems to me."
	14	Have I read that correctly?
14:19:31	15	A. You did.
	16	Q. Do you have a response to that?
	17	A. Again, I I don't know that I'm not absolutely
	18	certain it's my quote.
	19	Q. Okay. And then he had several questions for
14:19:41	20	you. I'd like to read the first and third.
	21	A. Okay.
	22	Q. "After I sent the article to you, you responded
	23	with the comment, 'balanced and fair.' Is that still
	24	your assessment, or on reflection, do you think your
14:19:55	25	quote was taken out of context?"

	1	Do you have an answer to that?
	2	A. Do I think my quote was taken out of context is
	3	the question.
	4	Q. Yes, sir.
14:20:03	5	A. I'm not sure.
	6	Q. And then the other question is: "Would
	7	receiving money from a law firm representing plaintiffs
	8	(suing Monsanto alleging that exposure to Roundup caused
	9	their NHL) constitute a conflict of interest that should
14:20:24	10	be disclosed when submitting comments to EPA or
	11	testifying before a public body like the EU, for
	12	example."
	13	And then he says: "I haven't looked into the
	14	specific disclosure requirements in the EU."
14:20:37	15	Do you have an answer to that question?
	16	A. The answer is yes. That's why I disclosed them
	17	in both cases.
	18	Q. I want to talk a little while about
	19	epidemiology, sir.
14:20:52	20	Last Thursday, on your first day of direct
	21	examination, Mr. Wisner said he'd be bringing in an
	22	epidemiologist to testify in detail about the
	23	epidemiology, and you said good.
	24	Why did you say "good"?
14:21:05	25	A. I don't want to be in San Francisco for the next

	1	three weeks.
	2	Q. That's a good answer.
	3	And in your expert report we'll go look at it
	4	if you need it, but see if you recall when you start
14:21:18	5	your section on epidemiology, you say other experts will
	6	be discussing the studies as well as their strengths and
	7	their weaknesses. I will focus on using the results of
	8	these studies in evaluating causality. I will only
	9	briefly describe each study."
14:21:33	10	Right?
	11	A. Correct.
	12	Q. So you wouldn't be the main person we would rely
	13	on to talk about the strengths and weaknesses of the
	14	epidemiology studies; is that fair?
14:21:41	15	A. This is my expert report on the all the
	16	studies. Certainly I know the strengths and weaknesses
	17	and I didn't put them in the expert report. That doesn't
	18	mean I don't know them.
	19	Q. All right. We've been told that Dr. Neugut, who
14:21:54	20	is a professor of epidemiology, Dr. Neugut, one of the
	21	expert epidemiologists for plaintiff, who was mentioned
	22	in opening statements, will testify that he's a professor
	23	of epidemiology at Columbia University, has an MPH in
	24	epidemiology. Would he be more qualified than you in
14:22:12	25	epidemiology?

	1	A. I would say yes.
	2	Q. And would you defer to him on issues of
	3	epidemiology?
	4	A. Not necessarily. I would
14:22:19	5	Q. You'd need to hear the issue?
	6	A. I'd need to hear the issue and then he would
	7	have to convince me if we were at odds.
	8	Q. Okay. Let me ask you this: Do you agree that
	9	one should not rely for causation on any positive
14:22:33	10	association in an epidemiology study that is not
	11	statistically significant?
	12	A. Say that again, please.
	13	Q. In finding whether causation exists or not, do
	14	you agree that you should not rely, for purposes of
14:22:47	15	causation, on any positive association in an epidemiology
	16	study that is not statistically significant?
	17	A. I don't quite know how to answer that question
	18	because it depends on where the emphasis is. Should I
	19	rely on associations from studies that are not
14:23:09	20	statistically significant? Yes, I should. I clearly
	21	have to look at them. The negative ones tell me as much
	22	as the positive ones. So certainly I have to consider
	23	them and rely on them in my in my judgment.
	24	If if you're that's the only answer I can
14:23:29	25	give. Yes, I would rely on all of them.

	1	Q. "Confounding occurs when there's an exposure or
	2	some other factor that is tightly associated with both
	3	glyphosate exposure and NHL, non-Hodgkin lymphoma,
	4	diagnosis that if controlled for could explain the
14:23:48	5	results."
	6	Do you agree with that?
	7	A. I agree with that.
	8	Q. And the most likely source of confounding in the
	9	epidemiology studies that we have discussed is exposure
14:23:57	10	to other pesticides.
	11	Do you agree with that?
	12	A. No. Exposure to some of those pesticides, yes.
	13	Clearly not all of them. I'd have to think about some of
	14	the other other confounders to decide if they're more
14:24:13	15	important. But pesticides are important.
	16	Q. Let me adjust the question slightly.
	17	The most likely source of confounding in these
	18	studies meaning the glyphosate ones would be
	19	exposures to some other pesticides.
14:24:27	20	A. Can we alter it a little more. The most likely
	21	see, they controlled for a bunch of other things
	22	besides the pesticides, even in the in the analyses
	23	where they said they didn't adjust for pesticides, they
	24	were still adjusting for other things, and those could
14:24:44	25	likely be strong confounders. But I wouldn't know


	1	because they adjusted for them. They don't show me the
	2	unadjusted.
	3	So I'm willing to say that the most likely
	4	confounders that were not adjusted for in the baseline
14:24:59	5	analysis are the pesticides.
	6	Q. You made written comments to EPA in October of
	7	2016; right?
	8	A. Correct.
	9	Q. And you and you address the issue of
14:25:11	10	confounding in these studies, and you've told them that
	11	it's fair to say that confounding could not be ruled out
	12	in these studies, talking about Eriksson and De Roos 2003
	13	and Cardell and Worsi; correct?
	14	A. And De Roos 2015 2005. All of them.
14:25:27	15	Q. 2005. And that's still your opinion today?
	16	A. Correct.
	17	Q. Now you briefly discussed a study called the
	18	NAPP study, the North American Pooled Project study, on
	19	Friday; right?
14:25:40	20	A. Yes. I was previously asked a question, if I
	21	remember.
	22	Q. Okay. And that combined all the US and Canadian
	23	study data; is that right?
	24	A. That's what they claim. I haven't seen any
14:25:56	25	paper on it.

	1	Q. There hasn't been a publication yet. Do you
	2	know why that is?
	3	A. No publication.
	4	Q. Do you know why that is?
14:26:02	5	A. No.
	6	Q. And Dr. Weisenburger, I believe is an expert
	7	witness for plaintiff, is one of the people involved in
	8	that project; correct? Have you ever asked him?
	9	A. I think he's involved in it. No, I have not
14:26:13	10	asked him.
	11	Q. Turn in your blue binder, sir, to 2867, please.
	12	A. I hate to say this, but I don't have 2867. 2811
	13	to 2882.
	14	Q. Here you are (indicating).
14:27:22	15	A. So 67.
	16	Q. I also gave you 2868 so I'll also be asking you
	17	about that.
	18	You know that the first of all, can you
	19	describe what you understand the North American Pooled
14:27:36	20	Project to be?
	21	A. Yes. It's a pooled evaluation of data from the
	22	three studies that were pooled for the De Roos 2003
	23	pooled analysis and the data from the study in Canada,
	24	McDuffie study.
14:27:55	25	Q. And it's not just an effort to come up with

	1	information about glyphosate-based herbicides; right?
	2	A. Correct. It's a pooled study of exposure of
	3	NHLs, but it is a broad range of exposure that they're
	4	looking at.
14:28:11	5	Q. They could look at other exposures and they
	6	could release study reports. They could release studies
	7	and published studies about other exposures; correct?
	8	A. Correct.
	9	Q. And they have done so?
14:28:22	10	A. That I don't know.
	11	Q. You don't know whether the North American Pooled
	12	Project has published other studies about other issues?
	13	A. That's correct. I do not know that.
	14	Q. All right, sir. Do you know that they ran
14:28:38	15	statistical tests and determined that several herbicides
	16	were confounders in their data?
	17	A. I've seen the slide decks that have been passed
	18	around. There are things like that in the slide deck.
	19	Q. Okay. Do you recall that they used statistical
14:28:59	20	tools to establish that herbicides 2,4-D and dicamba and
	21	the insecticide malathion were confounders?
	22	A. You would have to show me where and give me some
	23	indication of the methods used for the evaluation. The
	24	problem is all of these are just slide sets are
14:29:20	25	abstracts. An abstract is a short piece. And I don't

	1	feel there's enough information there for me to fully
	2	understand the study.
	3	Q. It would be nice to have a publication.
	4	A. If there was a publication on that and
14:29:34	5	glyphosate, yes.
	6	Q. Turn to 2868. That was the second tab I gave
	7	you because I assumed you didn't have that, either.
	8	That is a draft of an article; correct?
	9	A. It's an edited version, yeah. It's some sort of
14:30:00	10	draft.
	11	Q. So it's a little bit than a slide show or an
	12	abstract; right?
	13	A. I don't know. I don't think I've read this.
	14	Q. You haven't, sir?
14:30:08	15	A. I don't believe.
	16	Q. It says date of last revision, September 21,
	17	2015; correct?
	18	A. Correct.
	19	Q. And the date of the slide show that you looked
14:30:22	20	at on direct examination was from the summer of 2015;
	21	correct, do you recall?
	22	A. It's not on here, and I don't recall.
	23	MR. WISNER: Objection. I don't believe
	24	anything was shown on direct. Are you talking about
14:30:44	25	deposition?

	1	MR. GRIFFIS: Are you asking questions?
	2	MR. WISNER: No. I'm sorry.
	3	Q. BY MR. GRIFFIS: The numbers that you talked
	4	about on direct came from a summer 2015 slide show, or do
14:30:57	5	you know, sir?
	6	A. I don't know. I do not know.
	7	Q. Okay.
	8	A. I didn't rely on this information.
	9	Q. Okay. Why not?
14:31:05	10	A. Because it's not published.
	11	Q. Turn to page 8 of 19, sir.
	12	A. On which document?
	13	Q. The second, 2868.
	14	A. Okay.
14:31:23	15	MR. GRIFFIS: Permission to publish so the jury
	16	can follow along.
	17	THE COURT: Any objection?
	18	MR. WISNER: I think we need a sidebar, your
	19	Honor.
14:31:31	20	MR. GRIFFIS: If you say no, I'll just read.
	21	MR. WISNER: I think there's a bigger
	22	conversation.
	23	MR. GRIFFIS: Okay.
	24	(Sidebar.)
14:31:47	25	



		
	1	non-Hodgkin lymphoma, major histological subtypes, from
	2	the North American Pooled Project, N-A-P-P, NAPP, and
	3	date of last revision of this draft was September 21,
	4	2015.
14:33:24	5	And as we've both agreed, this hasn't ever been
	6	published; right?
	7	A. Correct.
	8	Q. On page 8, I'm just directing you to this so we
	9	can address that issue of confounding. And look at the
14:33:36	10	second paragraph under statistical analyses.
	11	A. Okay.
	12	Q. Starting "pesticides" over here.
	13	Pesticides that were most strongly correlated
	14	with glyphosate, and they give the statistics that you
14:33:52	15	wanted, I hope. And there were significantly or strongly
	16	associated with NHL and previous studies were evaluated
	17	as confounders. These were herbicides 2,4-D and dicamba
	18	as well as the insecticide malathion; correct?
	19	A. That's what it says, yeah.
14:34:22	20	Q. Let's go to 2867, the slide show. And this is a
	21	slide show with a number of data tables presenting data
	22	from this study; correct?
	23	A. Sorry. Yes.
	24	Q. Okay. If you'll turn to page 10 of this slide
14:34:44	25	show is a table entitled "Glyphosate Use and NHL Risks,"

	1	and there is an overall row, and then for various
	2	subtypes; correct? Subtypes of non-Hodgkin's lymphoma?
	3	A. NHL subtypes, number of cases. Yes, I think I
	4	found the right one.
14:35:08	5	MR. GRIFFIS: Permission to publish this.
	6	THE COURT: Any objection?
	7	MR. WISNER: No objection, your Honor.
	8	Q. BY MR. GRIFFIS: Let's actually start with the
	9	first page cover. And do you see a title and that one of
14:35:28	10	the authors is Dennis D. Weisenburger?
	11	A. Yes.
	12	Q. Okay. Now let's go to page 10. I'd like to
	13	focus on the overall risk reported here. We have an odds
	14	ratio A and an odds ratio B. And would you just tell the
14:35:56	15	jury what not what these specific A and B's mean, but
	16	what it means when you say odds ratio A and odds ratio B
	17	in a study as a tool for reporting?
	18	A. It's a superscript. It tells you to look at the
	19	bottom of the table, A to B.
14:36:11	20	Q. They've been adjusted and controlled for in
	21	different ways and look down to see the details? Okay.
	22	A. Correct.
	23	Q. So what is this column adjusted for
	24	statistically, the first column?
14:36:23	25	A. First column A? Odds ratios adjusted for age,

	1	sex, state and province, lymphatic or hematopoietic in a
	2	first-degree relative, use of a proxy respondent, use of
	3	any personal protective equipment.
	4	Q. And odds ratio B was controlled for what?
14:36:44	5	A. Odds ratio adjusted for all co-variants in model
	6	A. That means all the other ones that were already in A,
	7	plus use of 2,4-D, dicamba, use of dicamba, use of
	8	malathion.
	9	Q. And when they controlled for those pesticides
14:36:57	10	that they had found statistically to be confounders, what
	11	happened to the odds ratio?
	12	A. They went down.
	13	Q. And it was not statistically significant;
	14	correct?
14:37:06	15	A. The confidence bound now includes one.
	16	Q. Would you go to page 26, please, sir.
	17	Now I know that the NAPP data is not one of the
	18	ones you relied on so let me ask if you know this: Do
	19	you know that they found that controlling for proxy
14:37:36	20	versus self-respondents affected the data?
	21	A. I've seen these slides, yes.
	22	Q. So you know that that's true?
	23	A. I've seen the slide sets. I haven't seen the
	24	paper. I don't know exactly what it means because I
14:37:57	25	don't know exactly what they did.
		I I I I I I I I I I I I I I I I I I I

	1	Q. Yes, sir. Nobody's seen the paper.
	2	A. So I have to make an assumption to evaluate what
	3	they are saying there, and I don't know I don't know
	4	that my assumption will be correct.
14:38:12	5	Q. Let's start here. What's a proxy responder?
	6	A. Generally a proxy responder is when a person in
	7	the case-control study has passed away, they ask a
	8	relative to answer the questions for them.
	9	Q. And a self-respondent is the person himself or
14:38:31	10	herself; right?
	11	A. Correct.
	12	Q. It's generally thought that self-responders do a
	13	better job accurately reporting their exposures and their
	14	history than a proxy responder does; correct?
14:38:42	15	A. I don't think there's a generalization to be
	16	made there. But it can be different. It can be very
	17	different.
	18	Q. Okay. And when they controlled for
	19	self-respondents. Let's look at that column. This is
14:38:56	20	the never-ever figure. Never used glyphosate versus ever
	21	used glyphosate; correct?
	22	A. I assume that's what it is. That's what it
	23	says.
	24	Q. For self-respondents, what is the odds ratio and
14:39:12	25	the confidence interval?

	1	A. The odds ratio is .95 and the confidence
	2	interval is .69 to 1.32?
	3	Q. And what is the significance of the 0.95 odds
	4	ratio?
14:39:28	5	A. It's below one.
	6	Q. And one means what?
	7	A. One means there's no effect whatsoever.
	8	Q. Okay. And then we have three different measures
	9	of intensity. We have duration of use, number of years
14:39:42	10	of use and again, this is pooled data from all the
	11	North American, US, and Canada data; correct?
	12	A. I don't I don't there's a lot of problems
	13	with that in looking at this, and I just can't answer
	14	these questions. I didn't rely on this data because of
14:40:04	15	concerns. They had three slide sets or four slide sets,
	16	not one. In the four slide sets, there's different
	17	numbers. So which set of numbers am I supposed to
	18	believe?
	19	Then when you look at the total number of
14:40:17	20	members in the case-control study, it's more than any
	21	individual for in the individual studies from which
	22	they're pulling. So I don't know where they got the
	23	extra individuals from.
	24	There are so many unanswered questions about
14:40:32	25	this because there's not a publication, I'm very

	1	uncomfortable even commenting on it.
	2	Q. I'll ask you one more question then, and then
	3	we'll move on. It might be one of my slightly
	4	complicated questions, and I might have to ask you two.
14:40:48	5	But we've got duration, number of years. We've
	6	got frequency, number of days per year. And then we have
	7	a combination, lifetime days, number of years times
	8	number of days in the year. So that's the one that
	9	combines these other two in a, sort of, aggregate
14:41:04	10	frequency of use analysis; right?
	11	A. That that's normal.
	12	Q. Okay. And let's look at these results, and tell
	13	me whether they are at all statistically significant.
	14	A. You're just asking me to look at the numbers
14:41:27	15	Q. Yes, sir.
	16	A and tell you whether it's in contains one
	17	in the confidence bound or not?
	18	Q. Yes.
	19	A. I mean, that that's inherent just looking at
14:41:34	20	the numbers.
	21	Q. Thank you, sir.
	22	I want to talk to you a little bit about the
	23	2018 Journal of the National Cancer Institute, JNCI,
	24	study. And that is a study published by the AHS group;
14:41:48	25	right, the Agricultural Health Survey group?

	1	A. Agricultural Health Study.
	2	Q. Agricultural Health Study, I'm sorry.
	3	A. The authors are from that study.
	4	Q. And we need to make a distinction between the
14:42:00	5	AHS and the single publication journal of the National
	6	Cancer Institute 2018; correct?
	7	A. I didn't understand that.
	8	Q. Well
	9	A. The Andreotti publication in the JNCI 2018.
14:42:15	10	Q. The Agricultural Health Study isn't one study
	11	that culminated in the JNCI 2018; correct?
	12	A. Correct. There are multiple publications.
	13	Q. It's a big research project.
	14	A. Correct.
14:42:28	15	Q. So they're gathering data and have been
	16	gathering data for years they put out the De Roos
	17	2005, for example about agricultural exposures to many
	18	different chemicals and their associations with many
	19	different substances; right?
14:42:44	20	A. Correct.
	21	Q. And they're able to take that pooled data, take
	22	the parts that are relevant to a particular issue,
	23	analyze it, have their various experts work on it and do
	24	a publication on a particular issue; right?
14:42:59	25	A. Correct.


	1	Q. So although they have data on, for example,
	2	diesel fume exposure in the 1990s, they could do a study
	3	that has nothing to do with that, but focuses instead on
	4	glyphosate, for example?
14:43:12	5	A. Theoretically, yes.
	6	Q. Yes, sir.
	7	MR. GRIFFIS: Permission to publish the JNCI
	8	2018?
	9	THE COURT: Any objection?
14:43:22	10	MR. WISNER: No objection to the publication of
	11	the Andreotti paper.
	12	Q. BY MR. GRIFFIS: Okay. This is Defense
	13	Exhibit 2052.
	14	A. Blue?
14:43:34	15	Q. It is in your blue binder, I hope. It's in
	16	mine.
	17	A. Yes, it is.
	18	Q. And this is called "Glyphosate Use and Cancer
	19	Incidents in the Agricultural Health Study"; right?
14:43:49	20	A. Correct.
	21	Q. It's a study on glyphosate use and cancer;
	22	right?
	23	A. Right.
	24	Q. It's not on a whole bunch of other substances in
14:44:02	25	cancer; right?


1 I'm sorry, it's not about other diseases. Α. True. 2 It's cancer. 3 Q. Now, the first thing I want to talk about is your initial reaction to this publication coming out, 4 14:44:18 5 sir. A few days after this study was published, you 6 7 emailed a critique of it to a member of the press; right? 8 Α. I might have. 9 2407 in your binder. Q. 10 Okay. 14:44:49 Α. 11 Q. Let's -- I want to show you something. First 12 published online November 9, 2017; right? 13 A. Correct. Q. Okay. And now we have, at Tab 2407 of the blue 14 14:45:09 15 binder, an email that you sent on November 10th, 2017, to 16 a member of the press; right? 17 Α. Correct. 18 And you sent her expert reports from another Q. 19 epidemiologist in this litigation, for plaintiff's; 14:45:28 20 correct? 21 A. Correct. 22 In the emails, you criticized JNCI 2018 for Ο. 23 using an imputation method. And you said that, "It would 24 incorrectly classify as unexposed in a later time period 25 any subject of the study who had been unexposed in an 14:45:48


	1	earlier time period."
	2	And that was incorrect; right?
	3	A. I'm sorry, which sentence are you talking about?
	4	Q. It's the one under, "So to answer your
	5	questions."
	6	A. I'm sorry?
	7	Q. You say, "So to answer your questions," colon,
	8	and then there's a paragraph. That's the one I'm
	9	referring to.
14:46:19	10	A. "The study does add to the scientific data."
	11	"It does add to the scientific" so what I said, which
	12	was wrong, was that in the imputation, people who had no
	13	exposure in the previous request for doses would have no
	14	exposure in the imputed doses. That is incorrect.
14:46:43	15	Q. And you were, kind of, attacking before you
	16	properly understood the study; is that fair?
	17	A. No. I just misunderstood a small part of the
	18	study.
	19	Q. Okay.
14:46:53	20	A. The imputation. Or one part of it.
	21	Q. On November 12th, you sent an email that looks
	22	like it was actually cut-and-pasted from the text of the
	23	one you sent to the reporter. And you'll find that, sir,
	24	at Tab 2334.
14:47:18	25	This is to a government official in France


	1	involved with the EU's regulatory review of glyphosate;
	2	right?
	3	A. Say that again. I'm sorry.
	4	Q. It was to a government official in France
14:47:31	5	involved with the EU's regulatory review of glyphosate;
	6	right?
	7	A. It appears to be, yes.
	8	Q. And you were trying to influence the EU's
	9	response to and reaction to this paper; is that right?
14:47:43	10	A. No. He asked me a question. He sent me an
	11	email asking me what I thought of this particular paper.
	12	I wasn't attempting to influence the EU. I was answering
	13	his question.
	14	Q. Now I want to talk to you a little more about
14:47:59	15	imputation, sir.
	16	A. Sure.
	17	Q. Now, I mean, you said that that you
	18	misunderstood and got this part wrong in the emails that
	19	you sent.
14:48:08	20	So what you testified about imputation on Friday
	21	is about a somewhat different aspect of the issue; is
	22	that right?
	23	A. It's it's an it was testimony on
	24	imputation. I don't know what some other aspect means.
14:48:25	25	Q. Okay. Well, it's not the wrong thing that you


	1	said to the reporter and to the French official?
	2	A. It's it's it was not testifying about the
	3	fact that people who had no exposure before still had no
	4	exposure in the imputation, that's correct.
14:48:40	5	Q. Okay. And you recently gave a presentation
	6	about your views about the 2018 JNCI study. And you used
	7	slides that you made; correct?
	8	A. I give a lot of talks.
	9	Q. Okay.
14:48:55	10	A. Probably.
	11	Q. Let me see if I can find
	12	MR. GRIFFIS: I've lost track of break times,
	13	your Honor.
	14	THE COURT: This would be a good time for a
14:49:10	15	break. Do you wish to take it?
	16	MR. GRIFFIS: Okay. Why don't we do that.
	17	THE COURT: All right. Ladies and Gentlemen,
	18	we're going to take the afternoon recess now. We'll be
	19	in recess until five after 3:00 on the wall clock.
14:49:21	20	Please remember: Do not discuss the case. We'll see you
	21	again at 3 o'clock. Thank you.
	22	(Jury leaves courtroom.)
	23	
	24	
14:50:22	25	












	1	
	2	(Jury enters courtroom.)
	3	THE COURT: Welcome back, Ladies and Gentlemen.
	4	Dr. Portier remains under oath, and,
15:10:58	5	Mr. Griffis, when you're ready, you may continue.
	6	MR. GRIFFIS: Thank you, your Honor.
	7	Q. Sir, so we've been talking about the JNCI 2018
	8	study, and I would like to hand you one slide. And this
	9	is the only one I'm going to ask you about, from a
15:11:16	10	(indicating) presentation of yours about that study.
	11	Do you recognize that slide?
	12	A. No, not really.
	13	Q. No, sir?
	14	A. It it's a slide. But I have to see the
15 : 11 : 36	15	context from which it came. I don't
	16	Q. Okay.
	17	A. You could have removed something. Anything's
	18	possible. I don't know what this is.
	19	Q. Turn to Tab 3180.
15:11:54	20	A. I'm sorry, I don't have it.
	21	Q. Definitively my fault somehow.
	22	Please take a look at that and so that you'll
	23	understand the context. And then we'll talk about the
	24	one slide that I want to talk to you about, sir.
15:12:40	25	A. Okay. At least the title and content makes

	1	sense.
	2	Q. Okay.
	3	A. I still can't swear that's my slide exactly, but
	4	certainly the things on it are things I would say.
15:12:53	5	Q. Okay. So let's put up that slide.
	6	MR. GRIFFIS: I asked for permission from
	7	Mr. Wisner, and he's granted it.
	8	THE COURT: No objection?
	9	MR. WISNER: No objection, your Honor.
15:13:07	10	Q. BY MR. GRIFFIS: So it's entitled "Why
	11	Andreotti" which is the JNCI article "is
	12	Methodologically Unsound"; correct, sir? I think it's
	13	the 12th Number 12 in there.
	14	A. That's what it says.
15:13:24	15	Q. Okay. And then there are just two bullets:
	16	"Evaluations with imputed exposures are unreliable," and
	17	then, "Only reliable numbers are the complete case
	18	analysis."
	19	Will you please tell the jury what a complete
15:13:40	20	case analysis is?
	21	A. Sure. When you have a cohort study where
	22	large any number of people in the cohort study stop
	23	participating in the study until you have some percentage
	24	of them not there, you have multiple options as to how
15:13:59	25	you do your analysis. But the two obvious ones that



	1	
	2	
	3	
	4	(End sidebar.)
15 : 15 : 43	5	THE COURT: All right. You may proceed.
	6	Q. BY MR. GRIFFIS: All right. The JNCI article,
	7	let's go to that, so we can lay a little bit of
	8	groundwork there. Tab 2052 in your blue binder, I surely
	9	hope.
15:16:10	10	A. 2052?
	11	Q. Yes.
	12	A. Yes. Okay.
	13	Q. Okay.
	14	MR. GRIFFIS: Permission to publish the JNCI
15:16:35	15	2018 study?
	16	MR. WISNER: No objection.
	17	THE COURT: All right, Counsel. Proceed.
	18	MR. GRIFFIS: Let's have Slide 323, which is a
	19	callout from page 3.
15:16:50	20	No. No, no, no. I apologize.
	21	Q. Okay. So we are on page 3, sir, first column.
	22	This is under the "Results" section. It says, "Risk
	23	ratios and lag and intensity weights, lifetime days,
	24	et cetera."
15:17:51	25	And then you rate ratio. In top exposure

	7	
		quartile was 0.87 for NHL. And it gives a confidence
	2	interval; correct?
	3	A. Correct.
	4	Q. Okay. And that also corresponds to Table 2,
15:18:30	5	which is on pages 4 and 5 of the study. If you'll go to
	6	page 5.
	7	Under "Non-Hodgkin's Lymphoma," we have first
	8	of all, Table 2 is showing a bunch of different cancers
	9	and cancer subtypes; correct?
15:18:49	10	A. That is correct.
	11	Q. Okay. For non-Hodgkin's lymphoma, we have none,
	12	and then Q1, Q2, Q3, Q4. Would you explain what the Q's
	13	mean?
	14	A. Okay. This is the intensity weighted lifetime
15:19:04	15	days of glyphosate use in the health study. It's a
	16	complicated formula. How deep do you want me to get into
	17	it?
	18	Q. Oh, Lord. No formulas. Just "Q" means what
	19	word does "Q" stand for?
15:19:18	20	A. So they made this formula that created these
	21	exposure categories for what they call intensity weighted
	22	lifetime days. And they have a whole distribution of
	23	these from very small to very large. And they take
	24	one-fourth of them, that's Quartile 1. The next four
15:19:38	25	going in magnitude upwards is Quartile 2, et cetera.

Okay. So "Q" is for quartile? 1 Q. 2 "Q" is for quartile. Α. 3 Q. None is the unexposed group, A1 is the lowest dose group and Q4 is the highest; right? 4 5 A. Correct. 6 Q. And when we see --7 A. People with the -- with the top 25 percent of 8 the exposures. 9 Q. Okay. And there are other places on the 15:19:57 10 chart -- well, like over here, we have M1, M2. And 11 that's for Moiety 1 and Moiety 2, meaning there wasn't 12 enough data to make quartiles, so they made half? 13 A. Correct. Q. And a moiety is a half. And there are also 14 15 terciles on there. 15:20:13 16 A. Which are thirds. 17 Q. Okay. When they had an in between amount of 18 data. So non-Hodgkin's lymphoma, they had enough data 19 15:20:20 20 to do quartiles. And there is our figure again, 0.87 for 21 the highest exposed group, with a confidence interval of 22 0.64 to 1.20; correct? 23 A. That's correct. 24 Q. Okay. Now, there -- because of the issue of 25 imputation and because the author is -- of JNCI 2018 were 15:20:37

	1	aware that that was an issue, they did a number of checks
	2	on their procedure; correct?
	3	A. I'm not sure what you're talking about.
	4	Q. Well, they did a whole case analysis, for
15:20:57	5	example; right?
	6	A. They presented one number for the whole case
	7	analysis.
	8	Q. And that number was 1? On page 4?
	9	A. Yeah. It's on page 4. Let's see. There it is.
15:21:20	10	1.04 for relative risk, Quartile 4.
	11	Q. It's it's the one in the middle, isn't it?
	12	"To evaluate" let me show you. Starting here
	13	(indicating).
	14	"To evaluate the impact of using computed
15:21:42	15	exposure data for participants who did not complete the
	16	follow-up questionnaire. We limited the analysis to
	17	34,698 participants who completed both questionnaires?"
	18	So that's what we were talking about for a whole
	19	case analysis. You just leave out the people who didn't
15:21:59	20	complete the second questionnaire and look at the ones
	21	who completed both, which is a smaller group of people,
	22	but you can just run those numbers; right?
	23	A. I'm still trying to find it. Hold on a minute.
	24	Okay. I found it.
15:22:16	25	Not totally. So they they collected exposure

	1	data in 2000 to 2005 in a rapidly so they there
	2	were a lot of options for how they could have analyzed
	3	these data. But I wanted to see to give me a complete
	4	case is they they obtained information on exposures
15:22:40	5	for people from 2000 to 2005.
	6	So I would have wanted to see a case where they
	7	only used people who responded to the questionnaire, and
	8	they used data up until 2005 or '6 or '7, something
	9	close, on the NHL cases. And that's the number I was
15:23:01	10	quoting. That's where that comes from.
	11	Q. Okay. The number that I quote I mean, the
	12	line that I've highlighted, it's also a whole case
	13	analysis, because it's limiting the data to people who
	14	answered both questionnaires; right?
15:23:14	15	A. Correct. But it's assigning exposure in 2012
	16	and 2011 based upon exposure experience in 2000 and 2005.
	17	Q. The numbers from that whole case analysis are
	18	0.90 relative risk, Quartile 4, the highest dose group;
	19	correct?
15:23:33	20	A. Correct.
	21	MR. GRIFFIS: You can highlight that, if you can
	22	see.
	23	Q. And the confidence interval is 0.63 to 1.27;
	24	right?
15:23:44	25	A. That's correct.

	1	Q. And then they also did the exposure that you
	2	wanted, the analysis that you wanted; correct?
	3	A. Correct. It's
	4	Q. And the relative risk for the highest exposure
15:23:55	5	quartile was what?
	6	A. 1.04.
	7	Q. With a confidence interval of what?
	8	A7 to 1.57.
	9	Q. So the numbers don't change much when you do the
15:24:07	10	controls for imputation; correct?
	11	A. They change somewhat, but the exposure
	12	misclassification beyond that also can take you down to a
	13	relative risk of 1. So it's it's slightly better in
	14	terms of a more stable number.
15:24:26	15	Q. You know how yesterday you were talking about a
	16	15 percent error that you calculated with regard to the
	17	imputed group?
	18	A. It's a 7 I didn't calculate it. Heltsche has
	19	it in his paper. It's a 7 percent misclassification of
15:24:43	20	the group that is imputed for exposures.
	21	Q. And you said that goes both directions, so it
	22	turns out to be 14 percent?
	23	A. No.
	24	Q. And your best estimate was 15? Okay. I totally
15:24:57	25	misunderstood your 15 percent number. Would you tell me

I

	1	what it is?
	2	A. I'm not sure I remember it myself.
	3	Q. Okay.
	4	A. The number 7.8 percent, when they tried to
15:25:08	5	impute exposures in people for whom they had the
	6	exposure, that estimate came out to be wrong, with
	7	7.8 percent of the people who said they were exposed
	8	being classified by that algorithm as unexposed.
	9	Q. And when we're looking at the all the people
15:25:29	10	in the study, we're looking at that number, the the
	11	7.8 percent, is that the number we're using for the
	12	error?
	13	A. I have it right here.
	14	Q. Okay. Tell me the correct number to use for
15:25:41	15	that.
	16	A. It was in those slides. What was that slide?
	17	It's in the back; right?
	18	7.31 percent.
	19	Q. 7.21?
15:25:59	20	A. 31.
	21	Q. 7.31. Okay.
	22	And that applies to the 36 percent of the group
	23	that's imputed; right?
	24	A. Well, no. That's I'll try to do it as simply
15:26:16	25	as possible.

	1	Okay. What Heltsche gave us was the number
	2	provided in their paper was an estimate of the number of
	3	people who responded saying they were exposed in the
	4	group they held off to the side. And then what he gave
15:26:42	5	us was the number of people he predicted to be positive,
	6	using his algorithm for prediction. Okay?
	7	Now, the problem with that number, 7.31 percent
	8	there, is that's the best case. That only occurs if
	9	every one of those estimates of people who were exposed
15:27:10	10	match an actual person who was exposed. But, of course,
	11	that's not the case. It's not likely to be the case.
	12	There's going to be people that the algorithm estimates
	13	are exposed who are not really exposed.
	14	Q. I'm sorry?
15:27:25	15	A. So that 7.31 percent is only in the margins.
	16	The total number of the total amount of
	17	misclassification could be as high as 98 percent.
	18	Q. 7.31 percent, that was your best estimate?
	19	A. 7.31 percent.
15 : 27:45	20	Q. Okay. That's of the imputed group could be
	21	misclassified or is likely to be the right number of
	22	misclassified from that group?
	23	A. No.
	24	Q. Okay.
15:27:54	25	A. That's the best case scenario. The likely

	1	number is somewhere between 7.3 and 98 percent.
	2	Q. And the part I'd like to focus on is it's out of
	3	the 36 percent; right?
	4	A. It's out of the 36 percent.
15:28:08	5	Q. Okay. And out of the 36 percent, we already
	6	know from Questionnaire Number 1, which they did fill
	7	out, that 75 percent of them were exposed; right?
	8	A. Something in that range. But I don't know if
	9	that's the same group.
15:28:20	10	Q. If they were exposed if 75 percent of the
	11	people who filled out who were missing from the second
	12	questionnaire filled out the first questionnaire and said
	13	they were exposed, we still know they were exposed.
	14	We've got them right; right?
15:28:38	15	A. No. It's an imputed doses for them. And that
	16	imputed dose may be 0.
	17	Q. As far as whether they are exposed were right?
	18	A. But they didn't give me the exposed yes/no. And
	19	I don't know what number they would have chosen. They'd
15:28:52	20	have to tell me what they meant by "ever exposed."
	21	If that were the case, then it would have been
	22	80-something percent exposed. But that analysis is not
	23	shown here.
	24	Q. I'm going to ask you one more question. Then
15:29:05	25	move on to 7.31 percent times 36 percent, the imputed

	1	group, times 25 percent, the group for which we didn't
	2	previously have exposure information, because they didn't
	3	say they were exposed back at the time of the first
	4	questionnaire, is a number less than 1 percent; right?
15:29:24	5	A. I have no idea what you're calculating. So I
	6	don't know what you're trying to calculate here.
	7	Q. Okay.
	8	A. I told you it could be 7.31 percent or
	9	98 percent. So you could completely mischaracterize
15:29:41	10	every single exposed and almost every single unexposed
	11	and still get the 7.31 percent agreement a
	12	disagreement that Heltsche showed. Because Heltsche
	13	didn't show me how many exposed he missed and how many
	14	unexposed he missed. I can't I can't answer the
15:30:02	15	question.
	16	Q. I think it may not be too productive for us to
	17	get to the bottom of this today.
	18	There's a whole bunch of articles about the
	19	both the agricultural health survey agricultural
15:30:15	20	health study and its methodologies, its methods of data
	21	collection and analysis, studies, analyzing it and
	22	assessing the accuracy of it, validating its methods and
	23	improving its methods.
	24	And there are a number of studies analyzing
15:30:31	25	things like the imputation method that were used. All

	1	those are published and peer-reviewed in the
	2	agricultural NCI 2018 is, of course, published and
	3	peer reviewed; is that right?
	4	A. There
15:30:45	5	MR. WISNER: Objection. Compound. The lawyer's
	6	testifying.
	7	THE COURT: All right. Sustained.
	8	Please break it down, Mr. Griffis.
	9	MR. GRIFFIS: Yes, sir.
15:30:52	10	Q. JNCI is published and peer-reviewed; right?
	11	A. The Andreotti paper in 2018 was published in the
	12	journal JNCI.
	13	Q. And there's a cloud of other papers that have
	14	been published with regard to the methods and methods of
15:31:09	15	analysis of both the Agricultural Health Study and this
	16	paper itself; right?
	17	A. There are many, many papers, correct.
	18	Q. Let's leave it at that.
	19	This is a slide from your direct examination,
15 : 31:35	20	sir, showing a progression of cancer cells.
	21	A. Correct.
	22	Q. All right. This is a process that you told the
	23	jury receives from normal cells to damaged cells to
	24	mutated cells. And you have more stages there. You've
15:31:51	25	left off a number of details, because this isn't an

	1	oncology class. And then cancer; correct?
	2	A. I'm sorry? What was that last part? I didn't
	3	understand. I didn't hear it.
	4	Q. You left off a number of steps. It says, "More
15:32:03	5	steps." We didn't go into those steps. And I said,
	6	"Because this isn't an oncology class." In other words,
	7	it would be complicate to explain all those steps. And
	8	then at the end, we have cancer; right?
	9	A. They're somewhat repeated steps.
	10	Q. Okay.
	11	MR. WISNER: Just for the record, this is
	12	Exhibit 1024.
	13	Q. BY MR. GRIFFIS: This is a process that takes
	14	time; right?
15 : 32 : 26	15	A. It can, yes.
	16	Q. And you've given testimony in your critique and
	17	your analyses to regulatory agencies about glyphosate and
	18	non-Hodgkin's lymphoma with regard to the fact that this
	19	is a process that takes time; right?
15:32:43	20	A. I've not really. I gave testimony from a
	21	number of published papers on NHL. And then as to how
	22	fast it comes up. But I'm no expert there.
	23	Q. Yes, sir. And that came up because of the issue
	24	of the De Roos 2005, which is from the Agricultural
15:33:09	25	Health Study project, and a critique of yours that that

	1	study may underestimate risk because the median follow-up
	2	time is just 6.7 years; right?
	3	A. That's correct. It's a it's a cohort study.
	4	So you have to get enough patients with the disease
15:33:31	5	before you can actually start seeing a significant
	6	effect.
	7	And so you have to accumulate them. You're
	8	starting with 0 NHL patients, and you must accumulate
	9	them over time. And that's what the follow-up time is.
15:33:44	10	Q. All right. And 6.7 years, you were saying, may
	11	not be enough time to start to see adequate cases to get
	12	a good result; right?
	13	A. Correct.
	14	Q. Okay. Because cancer takes time.
15:33:56	15	A. That's because it takes time to build a cohort
	16	of people with enough cancers.
	17	Q. And you gave testimony to EPA on the subject of
	18	the latency of non-Hodgkin's lymphoma; correct?
	19	A. I I gave them some references in my
15 : 34 : 13	20	interpretation of the references.
	21	Q. Yeah, you gave them written comments, not
	22	testimony
	23	A. Correct.
	24	Q from your mouth.
15:34:23	25	2929, which is probably in Trial Cross 2, is

	1	your October 14, 2016, comments to the EPA, sir.
	2	A. 29?
	3	Q. 2929.
	4	A. No, not that one.
15:35:13	5	Q. We're almost done, sir.
	6	A. That's that's fine. I just can't find it.
	7	Which one do you think it is?
	8	Q. I think it is I'm sorry. Trial Cross 2.
	9	Yes, 2929.
15:35:32	10	A. Trial Cross Exhibits 2 and 2929 something?
	11	THE COURT: 2929.
	12	THE WITNESS: I'm afraid I don't have that one
	13	here either, unless I have the wrong folder. It says
	14	oh, this is regulatory documents. Sorry.
15:36:01	15	(Interruption in proceedings.)
	16	MR. WISNER: Your Honor, may I approach and help
	17	him?
	18	THE COURT: Yes.
	19	THE WITNESS: Thank you for waiting.
15:36:26	20	Q. BY MR. GRIFFIS: Okay. You found it, sir?
	21	A. Yes.
	22	Q. So these are written comments that you gave to
	23	the EPA on October October 4th, 2016; correct?
	24	A. Correct.
15:36:36	25	Q. And they're in the form of a statement by EPA

	1	I'm looking at page 6, for example where it says, in
	2	the middle of the page, Number 4, "Recall bias is a
	3	concern. Especially in the case control studies."
	4	"Comment: I agree."
15 : 37:01	5	A. Page 7?
	6	Q. Page 6.
	7	A. Page 6. Sorry.
	8	Let me put this in context, so I know what I'm
	9	saying here.
15:37:17	10	Q. Yes. I don't have a question about that. I'm
	11	just trying to establish how this document works.
	12	They're making a comment, and you're responding to the
	13	comment; right?
	14	A. Correct. "Recall bias is a concern. Especially
15:37:29	15	in" well, they say, "in the case control studies." I
	16	probably read it as "in case control studies."
	17	Q. Okay. I'm not actually intending to ask you
	18	about that one. I'm just asking how this works.
	19	And then the next question or comment by EPA
15:37:44	20	I'm sorry. Let's go down to 6.
	21	A. Okay.
	22	Q. Item 6: "The follow-up time in the De Roos, et
	23	al, 2005 study is sufficient that it should be given more
	24	weight than the other studies."
15:37:55	25	And then you had a comment in response to that;

	1	right?
	2	A. Yes.
	3	MR. GRIFFIS: Ask permission to publish 2929,
	4	the October 4th, 2016, comments of Dr. Portier?
15:38:07	5	THE COURT: Any objection?
	6	MR. WISNER: No objection.
	7	THE COURT: Very well. You may proceed.
	8	Q. BY MR. GRIFFIS: Let's go to page 6, at the
	9	bottom.
15:38:24	10	Okay. "So as noted by Portier, et al" this
	11	is your comment. You're citing yourself
	12	A. Right.
	13	Q in one of your publications. "The median
	14	follow-up time in the AHS study was 6.7 years, not 7, and
15:38:36	15	there is a question of whether this is long enough."
	16	And then you start to talk about some of the
	17	literature on how long it takes for non-Hodgkin's
	18	lymphoma to develop; correct?
	19	A. Correct.
15:38:47	20	Q. And the question I mean, the epidemiological
	21	question here is that we're trying to find out whether
	22	exposure to glyphosate causes cancer. And if you do a
	23	study where you expose people to glyphosate and then
	24	check them six months later, that's not enough time,
15:39:04	25	right?

	1	A. That, I don't know.
	2	Q. Well, that is the general issue, whether the
	3	period of time from exposure to checking whether they
	4	have the disease is long enough; right?
15 : 39 : 17	5	A. No. We're talking about first this first
	6	talks about a follow-up time. That's not what follow-up
	7	time is. Follow-up time is from the beginning of the
	8	study until the time you evaluate something.
	9	And you have to have a long enough follow-up
15:39:35	10	time to have enough cases to be able to do the
	11	evaluation.
	12	Then I went into discussion of latency, which is
	13	a different thing.
	14	Q. Okay. Tell us what latency is.
15:39:45	15	A. Latency is the time from first exposure to
	16	our if you can estimate it, from exposure to the onset
	17	of the disease.
	18	Q. Okay. And the two have something to do with
	19	each other?
15:39:56	20	A. Latency has a distribution to it.
	21	Q. Okay.
	22	A. Some people are very susceptible, and it happens
	23	fast. Other people are very resistant, and it takes a
	24	very long time.
15:40:09	25	Latency and follow-up time have somewhat of a

	1	relationship. But it's not that strong of a
	2	relationship. If the latency for everybody is ten years
	3	minimum, then the follow-up has to be at least ten years
	4	in a case well, no. That's not true. Because in a
15:40:32	5	cohort study, people could have been exposed nine years
	6	earlier, and you'd see your first case one year into the
	7	study, because the latency is way back then.
	8	So they're not actually that related to each
	9	other.
15:40:45	10	Q. Okay. Let's talk about your discussion to the
	11	EPA of the issue of latency, which is the time between
	12	exposure to a substance, if that substance is going to
	13	cause cancer, and the cancer.
	14	And let's look at the next page, please.
15:40:58	15	So first of all, up here you're talking about
	16	Weisenburger 1992. That's a publication; right?
	17	A. That's correct.
	18	Q. And he says that, "The latency for NHL following
	19	environmental exposure is largely unknown." And then he
15:41:13	20	talks about some information like chemotherapy and
	21	radiation treatment; correct?
	22	A. Correct.
	23	Q. Okay. And then part of your comment is right
	24	here, "These are rather extreme exposures relative to
15:41:33	25	those from glyphosate."


	1	And by rather extreme exposures you're talking
	2	about chemotherapy and what else?
	3	A. Radiation.
	4	Q. Okay. So radiation and chemotherapy treatment
15:41:45	5	are both extremely cancer generating because of the way
	6	they operate; right?
	7	A. Well, chemotherapy, because it is aimed at
	8	killing cells and damaging quite a bit to try to get the
	9	cancer to go away, many chemotherapeutic agents are
15:42:13	10	they call them secondary cancers. They create secondary
	11	cancers. And sometimes very rapidly. But, yes,
	12	they're they're big exposures.
	13	Q. So your comment was, "These are rather extreme
	14	exposures relative to those from glyphosate, and it would
15:42:28	15	not be surprising for the glyphosate lag time to be
	16	longer than that from chemotherapy and radiation
	17	treatment, as suggested by Weisenburger, et al"; right?
	18	A. That's what it says.
	19	Q. And the latency was from 1 to 11 years, and up
15:42:41	20	to 16 in these papers that you said were probably on the
	21	short side compared to glyphosate; right?
	22	A. This that's what it says, but I should have
	23	used "median lag time" and "median latency," because it's
	24	an entire distribution, as I pointed out before. And so
	25	you may


	1	Q. It's an entire distribution? Is that what you
	2	said?
	3	A. It's an entire distribution of times. And
	4	people who are sensitive to massive dose could be
15:43:12	5	sensitive to low dose as well. So it still may include
	6	very short periods of time. But your distribution would
	7	spread out. So more people would have longer periods
	8	before they would see the glyphosate toxicity.
	9	Q. And there would be a curve?
15:43:27	10	A. There's a whole curve to it, yes.
	11	Q. Sort of a bell curve
	12	A. Correct.
	13	Q distribution?
	14	Now, you've also testified on this subject
15:43:36	15	before the Scientific Advisory Panel; correct?
	16	A. I did not testify, no.
	17	Q. Okay. You presented comments to the SAP?
	18	A. I sent in written comments.
	19	Q. Okay. And they discussed your comments; right?
15:43:46	20	A. This these are the written comments that went
	21	to that meeting.
	22	Q. All right.
	23	A. As well as two follow-ups.
	24	Q. Okay. Let's take a look at SAP's discussion of
15 : 43:56	25	your comments.
		1 1


	1	A. Okay.
	2	Q. This is 2440.
	3	A. Same book?
	4	Q. Regulatory 2.
15:44:30	5	A. Okay.
	6	Q. All right, sir. And I am on page I'm on
	7	age 37.
	8	A. Okay.
	9	MR. GRIFFIS: Permission to publish the SAP's
15:45:02	10	indings on latency?
	11	THE COURT: Any objection?
	12	MR. WISNER: Provided there's no objection if we
	13	oublish when we use it, no.
	14	THE COURT: All right. Very well.
15:45:13	15	You may proceed.
	16	Q. BY MR. GRIFFIS: On page 36. That's actually
	17	reah. This is the section on latency; correct?
	18	A. I've got it.
	19	Q. Okay. All right. And at the top of page 37,
15 : 45 : 38	20	the next page, they talk about you, "For instance,
	21	Portier, et al, 2016, stated that the follow-up period in
	22	e Roos, et al, is not long enough to account for cancer
	23	atency."
	24	So the follow-up period, you explained what that
15 : 45 : 55	25	s, isn't long enough to account for cancer latency, and

	1	you explained how that's a separate but related concept;
	2	correct?
	3	A. Yes. It was separate and a different concept.
	4	I don't agree with the sentence I have here, but
15:46:09	5	Q. I'm sorry?
	6	A. They've misquoted me.
	7	Q. Okay. What would be the correct quote?
	8	A. Well, I dealt with latency separate from
	9	follow-up time.
15:46:20	10	Q. All right.
	11	A. And they've they've brought them together and
	12	say it's not long enough. I don't think I ever said
	13	that.
	14	Q. "Panelists has also noted" now I'm down at
15:46:30	15	the bottom. "Panelists also noted the evidence presented
	16	by Weisenburger 1992, who stated that while median
	17	latency for NHL was five to six years for high exposures
	18	to chemotherapy or radiation, it is expected to be much
	19	longer for lower exposures."
15:46:50	20	That paper goes on to state that, "A median
	21	range of 15 to 20 year latency is plausible for lower
	22	chronic exposures"; correct?
	23	A. That's what it says.
	24	Q. So do you believe that Dr. Weisenburger's
15:47:05	25	statement that Dr. Weisenburger's correct, that median

		
	1	latency for NHL would be five to six years for intense
	2	exposures like chemotherapy or radiation?
	3	MR. WISNER: Objection. Hearsay within hearsay.
	4	THE COURT: Overruled.
15:47:18	5	You may answer.
	6	THE WITNESS: Can I see the Weisenburger paper?
	7	I certainly know that in the Weisenburger paper the
	8	median latency he cited is five to six years based upon
	9	the cases he looked at.
15 : 47 : 33	10	But I don't know that he went on to say the
	11	other thing about median 15 to 20. It wouldn't surprise
	12	me, but I'd love to see the paper.
	13	Q. BY MR. GRIFFIS: Let me show you this. Look at
	14	2749. In the yeah, not in the regulatory binder. In
15 : 47 : 47	15	the blue binder.
	16	A. Okay.
	17	Q. So these are the written comments of
	18	Dr. Weisenburger to the EPA?
	19	A. I don't have it.
15:48:08	20	Q. Oh, of course.
	21	MR. WISNER: Your Honor, I'm going to object.
	22	Can we have a sidebar on it?
	23	THE COURT: Yes.
	24	MR. GRIFFIS: Hand you that, sir.
15:48:24	25	(Sidebar.)









	1	Q. And commenting about his 1992 paper; correct?
	2	A. If I remember his comments, yes, correct.
	3	Q. Okay. And have you seen those comments?
	4	A. Yes, I did read the comments.
15 : 52 : 21	5	Q. Is that what this is (indicating)?
	6	A. It looks like it, yes.
	7	Q. Now, he in he says, "This statement of the
	8	EPA document implies" let's back up.
	9	This is a letter from Dr. Weisenburger to
15:52:40	10	Steven Knott at the US EPA, where a comment to the EPA
	11	issued paper on glyphosate, dated September 12th, 2016.
	12	"Dear, Mr. Knott, I am providing the following comments
	13	to the EPA regarding the above cited document. On page
	14	67 of this document, it states that the latency period
15:52:57	15	for non-Hodgkin's lymphoma, NHL, in general is unknown
	16	and that estimates range from 1 to 25 years, with a
	17	citation to my 1992 paper," and then he gives the cite;
	18	right?
	19	A. Correct.
15:53:10	20	Q. Okay. This statement in the EPA document
	21	implies that the range of latency period for glyphosate
	22	exposure and the potential development in NHL is likely
	23	to be within the range, i.e., the range of 1 to 25 years;
	24	correct?
15:53:26	25	A. That's my interpretation of the sentence.

	1	Q. Okay. "Such an interpretation from my 1992
	2	paper is incorrect. As stated in the paper, the latency
	3	period for NHL would be short following cancer treatment
	4	with chemotherapy and/or radiation, e.g. 5.6 years, and
15:53:48	5	for atomic bomb survivors, about 9 years, with a longer
	6	latency for those receiving smaller doses. I further
	7	stated that long-term low-level exposure would be
	8	expected to result in a long latency period."
	9	Am I doing well reading so far?
15:54:05	10	A. You're doing fine.
	11	Q. Okay. Do you disagree with anything he said so
	12	far about his 1992 paper on latency?
	13	A. I think he's he's missed a couple of years in
	14	here. In his paper, it's median was 5 to 6 years
	15	Q. Okay.
	16	A not exactly 5 to 6 years. And for atomic
	17	bomb survivors, it's it's a little more complicated
	18	than his 9-year number in his paper. He's just, kind of,
	19	drawing one number from a much more complicated.
15:54:36	20	Q. Okay. He's kind of summarizing a more detailed
	21	picture than inside his 1992 paper as far as atomic bomb
	22	survivors?
	23	A. Correct. Some of those people had had
	24	leukemia within one year and others still don't.
	25	Q. Okay.

	1	A. So it's a complicated picture.
	2	Q. All right. It's not everyone at nine years.
	3	It's a distribution.
	4	A. Correct.
15:54:52	5	Q. But the median was nine years; right?
	6	A. He gave several medians. He didn't give one.
	7	Q. Okay. All right. "I further stated" I'm
	8	quoting from the letter again. "I further stated that
	9	long-term low-level exposure would be expected to result
15:55:06	10	in a long latency period. For example, the average
	11	latency period for the development of NHL due to
	12	long-term low-level exposure to organic solvents is about
	13	20 years."
	14	And do you agree with that, that the average
15:55:21	15	latency period from NHL for long-term low-level exposure
	16	to solvents is about 20 years?
	17	A. I have no idea.
	18	Q. Okay. "Since exposure to glyphosate would be
	19	expected to be long-term low-level exposure, the citation
15:55:34	20	of my paper for the proposition that a latency period for
	21	glyphosate exposure in relation to NHL can range from 1
	22	to 25 years would contradict the conclusion of my 1992
	23	paper.
	24	I would expect the average latency period for
15 : 55 : 52	25	glyphosate exposure in relation to potential NHL to be at





	1	forever sorry for that.
	2	A. That's what I'm here for.
	3	Q. Okay. Let's start off with some things that
	4	were covered on cross-examination. Let's start off with
15:58:30	5	the NAPP. Do you recall questions about the NAPP?
	6	A. I recall there were questions about the NAPP.
	7	Q. And that's a North American Pooled Project;
	8	right?
	9	A. Correct.
15:58:42	10	Q. And that's an epidemiology project that's
	11	looking at a bunch of North American studies and pooling
	12	the data?
	13	A. Correct.
	14	Q. And you haven't seen a publication on it yet,
15:58:52	15	have you?
	16	A. That's correct.
	17	Q. Why is that important to you?
	18	A. Well, many times draft publications don't stand
	19	the test of time if they go through all the authors of
15:59:02	20	the publication. Things change. Authors want it
	21	analyzed a slightly different way, et cetera. They want
	22	the conclusions written in a slightly different way.
	23	There's all kinds of changes that can that can come
	24	up.
15:59:17	25	Q. Do you recall on cross-examination being shown a


	1	draft manuscript?
	2	A. Yes, I do.
	3	Q. It had, like, redlines in it and everything?
	4	A. Correct.
15:59:26	5	MR. WISNER: Permission to publish, your Honor,
	6	Defendants' Exhibit 2868?
	7	THE COURT: Any objection?
	8	MR. GRIFFIS: No objection.
	9	THE COURT: Very well. You may proceed.
15:59:34	10	MR. WISNER: Thank you, your Honor.
	11	Q. So this is that document, Exhibit 2868.
	12	And do you see right here, date of last
	13	revision, September 21st, 2015?
	14	A. Correct.
15:59:42	15	Q. So we know that this draft is well over well,
	16	almost three years old?
	17	A. Yes.
	18	Q. Okay. Mr. Griffis showed you some portions of
	19	it. I want to show you some portions of it.
15:59:59	20	Let's look at page 12 of 9. And it says right
	21	here, "This report confirms previous analysis indicating
	22	increased risks of NHL in association with glyphosate
	23	exposure."
	24	Do you see that, Doctor?
16:00:15	25	A. Yes.


	1	Q. Okay. And then if we go down here to this next
	2	paragraph, "Our results are also aligned with findings
	3	from epidemiological studies of other populations that
	4	found an elevated risk of NHL for glyphosate exposure and
16:00:31	5	with a greater number of days per year of glyphosate use,
	6	as well as a meta-analysis of glyphosate use and NHL
	7	risks. From an epidemiological perspective, our results
	8	are supportive of the IARC evaluation of glyphosate as a
	9	probable Group 2A carcinogen for NHL."
16:00:54	10	Do you see that?
	11	A. Correct.
	12	Q. So based on what we've read here, at least the
	13	authors of the NAPP study are confirming IARC, aren't
	14	they?
16:01:02	15	MR. GRIFFIS: Objection. Leading.
	16	THE WITNESS: At one point.
	17	Q. BY MR. WISNER: Fair enough.
	18	MR. WISNER: I'm sorry. Was there an objection?
	19	MR. GRIFFIS: Yes, it was leading.
16:01:09	20	THE COURT: Overruled.
	21	Q. BY MR. WISNER: All right. I understand there
	22	was some other data in that NAPP study, Doctor, that was
	23	shown to you, that presentation. Do you recall that?
	24	A. I recall the presentation, yes.
16:01:34	25	Q. Doctor, do you recall that there was data about

	1	greater than two days of year per use?
	2	A. Yes.
	3	Q. And that data showed a positive association with
	4	NHL?
16:01:49	5	A. I lost the exhibit.
	6	MR. WISNER: Permission to publish, your Honor?
	7	It's Defendants' 2827.
	8	THE COURT: Any objection?
	9	MR. GRIFFIS: No objection.
16:01:58	10	THE COURT: Very well. You may proceed.
	11	Q. BY MR. WISNER: So this is the presentation
	12	we're talking about. And I'll just pop it up on the
	13	screen.
	14	Well, let's just start off with the overall,
16:02:11	15	never, ever. Doctor, this is the overall, never, ever
	16	data in this slide show?
	17	A. Correct.
	18	Q. And overall has a 1.43 statistical significance?
	19	A. Yes.
16:02:35	20	Q. And then it has all these different subtypes.
	21	Do you see that?
	22	A. Yes.
	23	Q. And there's obviously other that's statistically
	24	significant at 166?
16:02:45	25	A. Yes.

	1	Q.	Okay.
	2	А.	Well, the confidence bound doesn't include 1.
	3	Q.	Yeah. Well, just barely, but it doesn't
	4	include	1.
16:02:54	5		And to the best of your knowledge, FL, DL, BCL
	6	and SLL,	do those include T-cell lymphoma?
	7	A.	I don't know.
	8	Q.	Okay. Fair enough.
	9		Here's another chart that was not shown to the
16:03:16	10	jury.	
	11		All right. This is it says, "Frequently days
	12	per year	of glyphosate handling and NHL risks"; right?
	13	A.	Yes.
	14	Q.	Okay. And then it has between zero and two
16:03:28	15	days.	
	16		Do you see that?
	17	А.	Yes.
	18	Q.	And that's not an elevated or statistically
	19	signific	ant rate?
16:03:33	20	A.	Correct.
	21	Q.	And then we have greater than two days per year.
	22		Do you see that?
	23	А.	Yes.
	24	Q.	And that's more than doubling of the risk?
16:03:41	25	A.	Yes.

	1	Q. And it's statistically significant?
	2	A. Yes, it is.
	3	Q. And if you look across all the subtypes, it is
	4	also above 2 across the board.
16:03:49	5	Do you see that?
	6	A. Yes, I do.
	7	Q. And for FL, although it's not statistically
	8	significant, it's close at .99?
	9	A. Correct.
16:03:56	10	Q. And then it is statistically significant for DL,
	11	BCL.
	12	Do you see that?
	13	A. Yes.
	14	Q. Okay. And then these ones aren't significant,
16:04:05	15	but they're elevated.
	16	Do you see that?
	17	A. Yes.
	18	Q. Okay. And would that would those results be
	19	consistent with the portion of the manuscript we just
16:04:15	20	read to the jury?
	21	A. Yes.
	22	Q. Okay. All right. Let's look at
	23	MR. WISNER: Your Honor, permission to publish
	24	Defendants' Exhibit 3183?
16:04:39	25	THE COURT: Any objection?





	1	Q. All right. Now, the EPA convened as a science
		advisory panel; is that right?
	3	A. Correct.
	4	Q. And I'd like to show you would you recognize
16:07:03		a copy of that SAP panel report if you saw it here today?
	6	A. We had one in evidence, yes.
	7	MR. WISNER: All right. Permission to approach,
	8	your Honor?
	9	THE COURT: Yes.
16:07:15	10	MR. WISNER: I'm handing the witness Plaintiff's
	11	Exhibit 762.
	12	Q. Is that a copy of the SAP report, Doctor?
	13	A. Yes.
	14	MR. WISNER: Your Honor, permission to publish?
16:07:25	15	THE COURT: Any objection?
	16	MR. GRIFFIS: No objection, your Honor.
	17	THE COURT: Very well.
	18	Q. BY MR. WISNER: So this is the SAP report. It's
	19	dated March 16, 2017; right, Doctor?
16:07:38	20	A. Yes.
	21	Q. And this is Plaintiff's Exhibit 762. I'd like
	22	to turn your attention to page 18 of the document.
	23	A. I'm there.
	24	Q. There was a lot of discussion do you recall
16:08:01	25	on cross-examination there being a lot of discussion

	1	about whether or not the EPA followed their own
	2	guidelines?
	3	A. Yes.
	4	Q. And do you recall the SAP discussing that?
16:08:08	5	A. Yes, at several points.
	6	Q. Okay. I want to read this sentence in and ask
	7	what you understand it to mean.
	8	"Overall, the panel concluded that the EPA
	9	violation does not appear to follow the EPA cancer
16:08:24	10	guidelines in several ways. Notably for use of
	11	historical control data and statistical testing
	12	requirements."
	13	What does that mean, Doctor?
	14	A. It's very clear in what it means. There are
16:08:40	15	guidance in their cancer guideline document about when
	16	and how to use historical control data and what
	17	statistical tests to use and what are the requirements
	18	for using them and interpreting them. And they did not
	19	follow those guidelines.
16:08:55	20	Q. And this is not your opinion; is that right?
	21	A. No, this is not my opinion.
	22	Q. Whose opinion is this?
	23	A. This is the science advisory panel and their
	24	expert consultant's opinion.
16:09:07	25	Q. And I understand a guy by the name of

	1	Dr. Portier was on that panel; is that right?
	2	A. He was one of the expert consultants to the
	3	Q. And he was the one he's your brother; is that
	4	right?
16:09:18	5	A. He is my brother.
	6	Q. Now, the fact that he's related to you, doesn't
	7	that make him biased overall in his scientific
	8	assessment?
	9	A. I would hope not.
16:09:28	10	Q. Why do you say that?
	11	A. Because we were raised to not, sort of in
	12	scientific areas, we'd debate ourselves to death rather
	13	than try to believe one or the other if we didn't agree
	14	with it. So there shouldn't be a bias.
16:09:47	15	Plus, he and I never talked about it. So we
	16	specifically said we were not going to talk to each other
	17	about it when he was named to the panel.
	18	Q. Do you recall on cross-examination there was
	19	some conversation about a newspaper article that you were
16:10:02	20	quoted in? Do you recall that?
	21	A. Yes.
	22	Q. And in that newspaper article, there's a quote
	23	from you about your brother's potential impartiality.
	24	A. Okay. There probably was.
16:10:15	25	Q. Okay. What was the context of that?

	1	A. There was a push by two groups I think they
	2	were industry-supported groups to have my brother and
	3	one other panelist taken off the SAP.
	4	Q. And were these people who had been on the SAP
16:10:35	5	before?
	6	A. I don't know about the other panelists, but my
	7	brother was on the SAP as a member. SAP meetings have
	8	members and invited experts, and so he was a member of
	9	SAP for, I believe, seven years, and now he servers as an
16:10:53	10	invited expert sometimes.
	11	Q. And what was the basis of challenging his
	12	participation in that committee?
	13	A. He's my brother.
	14	Q. And did the EPA buy it?
16:11:01	15	A. No, they did not.
	16	Q. All right. Let's go back to this chart. It's
	17	Defendant's Exhibit 3183. It's this chart of agencies.
	18	Let's move on to the next three. Look at ECHA, EFSA and
	19	BfR. Okay?
16 : 11 : 27	20	A. Okay.
	21	Q. And let's just clarify. Are they essentially
	22	the same thing?
	23	A. BfR and EFSA, as far as glyphosate is concerned,
	24	are essentially the same, because they're all working
16 : 11 : 39	25	from they're working from the same document.

	1	ECHA is different, but the document that was
	2	created for ECHA comes basically from the same group, and
	3	the the review is basically a similar group, so, no,
	4	they're not very different from each other.
16:11:57	5	Q. And to be clear, BfR does the initial draft;
	6	right?
	7	A. Not in this case.
	8	Q. Okay. Who did the initial draft?
	9	A. The glyphosate task force.
16:12:08	10	Q. And that's an industry-sponsored group of
	11	scientists?
	12	A. I I guess that would be a description of
	13	them, yes.
	14	Q. And then they give a draft to BfR; is that
16:12:17	15	right?
	16	A. They gave BfR a huge draft, yes.
	17	Q. And then the BfR makes edits and sends it to
	18	EFSA?
	19	A. Yeah. Sometimes EFSA considers their approach a
16:12:29	20	peer review, which means they don't write anything, they
	21	review something written to them. BfR usually writes it
	22	themselves, but this time they didn't. They did a peer
	23	review, basically, editing and cutting and pasting and
	24	correcting things in the document.
16:12:44	25	Q. And would it be fair to say, then, that the

	1	version that BfR initially reviewed and edited, it
	2	contained verbatim passages written by industry?
	3	A. Yes. Although, I can only yeah yes. I
	4	mean, it's hard for me. These are these are these
16 : 13:07	5	documents are quite complicated, but in the reassessment
	6	report that BfR put out, in the first part of it, they
	7	talked about they took the draft from the glyphosate task
	8	force.
	9	Now, I assume all of their comments and changes
16:13:26	10	are in there, because it's a huge redline document in
	11	that sense, but there might be some that aren't, but
	12	there are a lot of verbatim parts of it from industry.
	13	Q. Okay. And actually, I just was reminded, this
	14	is kind of important, do you recall who wrote the
16:13:44	15	original OPP report for the EPA?
	16	A. No.
	17	Q. Okay. Well, let's take a look. It's actually
	18	in the Defendant's exhibits. It's in Volume 2, and it's
	19	Exhibit 2071.
16:14:01	20	A. Regulatory Volume 2?
	21	Q. That's right.
	22	A. 2071?
	23	Q. I think I'm wrong. It's your trial cross
	24	exhibit to is it there?
16:14:30	25	A. So the cross exhibits, but not regulatory?

	1	Q. That's right. No, it's not there either. So
	2	2071.
	3	A. Christopher Portier Trial Cross Exhibits,
	4	Volume 2?
16:15:05	5	Q. Yeah, is it in this, 2071?
	6	A. I don't have 2071 in here.
	7	Q. Okay. I've got it here. I got it. It's
	8	Exhibit 2437, Volume 2 Regulatory. I got it.
	9	A. That one I have.
16:15:52	10	Q. Okay. And what's the name of the author of the
	11	original CARC report?
	12	A. You're talking about the memorandum delivering
	13	the document to EPA?
	14	Q. That's correct.
16:16:06	15	A. It's two people, Jess Rowland and Carolyn
	16	Middleton.
	17	Q. And, Doctor, do you know anything about Jess
	18	Rowland?
	19	A. Never met him.
16:16:37	20	Q. Okay. All right. So let's move on to sorry.
	21	Back to these ones. We were discussing the EFSA and ECHA
	22	process, and I understand you and EFSA had a
	23	back-and-forth, and you published an article specifically
	24	represented to ECHA; is that right? Sorry. EFSA.
16:16:52	25	A. EFSA, yes.

	1	Q. Comparing EFSA and IARC; right?
	2	A. Correct.
	3	Q. And in that article, there were some questions
	4	by opposing counsel about whether or not you disclosed
16:17:01	5	the fact that you were working on glyphosate litigation.
	6	Do you recall that?
	7	A. Correct.
	8	Q. Did you disclose it in that open letter to the
	9	world?
16:17:09	10	A. In the open letter or in the article?
	11	Q. In the article.
	12	A. In the published article, it's clearly
	13	disclosed.
	14	Q. Okay. And why did you do that?
16:17:16	15	A. Because the journals required it. Any conflict
	16	of interest has to be published.
	17	Q. Now, I want to be clear. All 95 of those
	18	co-authors, were they also working as experts in
	19	glyphosate litigation?
16:17:29	20	A. No.
	21	Q. Okay. All right. I want to talk about
	22	something that came up on cross. You remember there was
	23	a discussion about the Kumar study?
	24	A. Yes.
16 : 17 : 42	25	Q. And there were some discussions about whether or

	1	not there was a virus in the colony. Do you recall that?
	2	A. Yes, I do.
	3	MR. WISNER: Permission to publish Plaintiff's
	4	1020?
16:17:52	5	THE COURT: Any objection?
	6	MR. GRIFFIS: No, I don't have an objection.
	7	Q. BY MR. WISNER: All right. Doctor, this is the
	8	mouse chart. We talked about it a little bit at length.
	9	We are talking about the Kumar study here.
16:18:09	10	Do you see that?
	11	A. Yes.
	12	Q. And firstly, is there any evidence whatsoever
	13	that there was actually a viral infection in that colony?
	14	A. Nothing I can find, other than that one sentence
16:18:18	15	in the EPA's document, and then in EFSA's original
	16	document, they had a sentence in there that was removed
	17	later and edited out because they couldn't find any
	18	documents. There was no documented blood cytogenicity
	19	testing going on.
16:18:38	20	Q. Why don't you turn to the Defendant's Regulatory
	21	Binder 1, and this one I'm sure about it. It's 2071.
	22	A. Okay. I have it here.
	23	Q. What is the document, sir?
	24	A. This is the to make it simple, this is the
16:19:04	25	ECHA document.

	1	Q. And this is where they discussed their
	2	classification of glyphosate?
	3	A. That's correct.
	4	Q. Okay. Now, if you turn to page 72 in the
16:19:14	5	document.
	6	A. Okay.
	7	Q. That first big paragraph at the very bottom, do
	8	you see, "During a teleconference"?
	9	Do you see that?
16:19:25	10	A. Where are we looking at?
	11	Q. So the first
	12	A. First huge paragraph?
	13	Q. The first huge paragraph, at the very bottom,
	14	starting, "During a teleconference."
16:19:39	15	A. Yes, I do see it.
	16	Q. All right. It says, "During a teleconference on
	17	carcinogenicity of glyphosate held by EFSA, it was
	18	mentioned by a US EPA observer that Kumar, 2001, study
	19	had been excluded from US EPA evaluation due to the
16:19:56	20	occurrence of viral infection that could influence
	21	survival as well as tumor incidences, especially those of
	22	lymphoma. However, in the study report itself, there was
	23	no evidence of health deterioration due to suspected
	24	viral infection, and thus the actual basis of EPA's
16:20:14	25	decision is not known."

	1	Do you see that?
	2	A. Yes, I do.
	3	Q. Do you agree with that sentence?
	4	A. Yes, I do.
16:20:19	5	Q. Why?
	6	A. Because every time anyone is asked for that
	7	evidence, it has not been produced.
	8	Q. So ruling out malignant lymphoma in males in the
	9	Kumar study because of a viral infection would not be an
16:20:35	10	appropriate scientific thing to do?
	11	A. If they really had the viral infection, they
	12	would you would not rule it out. You would you
	13	would take that into consideration, but without evidence
	14	of a viral infection, of course you keep it in.
16:20:50	15	Q. And to this day, has anyone ever shown you any
	16	evidence that there was a viral infection?
	17	A. No, none at all.
	18	Q. All right. One of the issues that came up on
	19	cross-examination was something called multiple
16:21:06	20	comparisons. Are you familiar with that?
	21	A. Yes.
	22	Q. And what is a multiple comparison?
	23	A. It's well, it's when you take a lot of
	24	statistical tests and you begin to worry about false
16:21:20	25	positive findings.

	1	Q. Now, Doctor, is there a difference when you're
	2	looking for false positives between a bunch of random
	3	different tumors appearing and the same tumors appearing
	4	over and over again?
16:21:35	5	A. Yes. They as I mentioned, you can you
	6	could count so that concept of false positives deals
	7	with the idea that each and every tumor you're looking at
	8	is independent of any other tumor you're looking at, so
	9	when I have two studies now, that's no longer the case,
16:21:57	10	because we're looking at the same tumor in the same
	11	strain in the same sex. And so then when you start
	12	looking at this idea of multiple comparisons, you also
	13	have to take into account the linkage across tissues to
	14	make sure that you don't make any mistakes. And when you
16:22:16	15	start seeing the same tumor showing up in multiple sites,
	16	you become very much not worried about the false positive
	17	problem.
	18	Q. Why is that?
	19	A. Because the chances of it replicating in two or
16:22:30	20	three or four studies is extraordinarily low by chance.
	21	Q. And did you calculate that probability?
	22	A. No, I didn't. I'm sorry.
	23	Q. Okay. Do you have a copy of your expert report?
	24	A. Yes, I do.
16:22:39	25	Q. Please turn to Table 15 in your expert report.
		1

	1	A.	Okay. This is the general expert report, not
	2	one	
	3	Q.	That's right.
	4	Α.	of the later ones?
16:23:05	5		Okay.
	6	Q.	What is this?
	7	Α.	This is where I look at the question of is it
	8	possible	that these findings arose by chance.
	9	Q.	And I see at the bottom of this, through across
16:23:19	10	all stud:	ies, you looked at the probability of seeing
	11	these typ	pes of tumors as many times as you did; is that
	12	right?	
	13	Α.	Correct.
	14	Q.	And how did based on that 1-percent
16:23:30	15	confidend	ce interval
	16	Α.	Okay
	17	Q.	what was the expected observation of these
	18	number o:	f tumors?
	19	Α.	4.6.
16 : 23 : 36	20	Q.	And how many did you actually see in the data?
	21	Α.	12.
	22	Q.	So more than three times as many as you would
	23	expect to	see?
	24	Α.	Correct.
16 : 23:45	25	Q.	What's the relevance of that?

	1	A. Again, you're doing what I said we shouldn't
	2	do
	3	Q. I'm sorry.
	4	A dumping all the sexes and species and animals
16:23:56	5	together.
	6	The important the really important parts of
	7	that come from the male mouse studies where you expected
	8	.4 tumors and saw 5. That's almost a twentyfold increase
	9	over what you would see expected, and the probability of
16:24:15	10	that is extremely small.
	11	And then you could see in the male
	12	Sprague-Dawley rats, you doubled what's expected.
	13	Although that's not going to be a small statistical
	14	p-value, it's still a big difference. The same is true
16:24:29	15	for the where am I here? The anyway, those are the
	16	big ones. But when you look at that, it becomes unlikely
	17	that all of those tumors arose by chance.
	18	Q. When you discuss multiple comparisons this way,
	19	is it ever appropriate to just disregard the fact that
16:24:48	20	you're seeing the same finding over and over again?
	21	A. No.
	22	Q. Based on your personal opinion and based on
	23	review of these studies of in pretty much extreme
	24	detail, what is your opinion about the likelihood of
16:25:03	25	these being the result of false positives?

	1	A. It's very, very, very low.
	2	Q. All right. Doctor, there was some discussion
	3	about the various mechanistic studies that you reviewed
	4	as part of your analysis. Do you recall?
16 : 25 : 28	5	A. Yes.
	6	Q. And then they went over how the EPA
	7	characterized certain studies as positive and whatnot.
	8	Do you remember that?
	9	A. Yes, I do.
16:25:36	10	Q. Okay. Let's just talk a little bit about some
	11	of those studies, because I want to make sure we all
	12	understand what they say. Let's start out with
	13	Cavusoglu, 2006.
	14	A. Okay.
16:25:47	15	Q. What did that show?
	16	A. That showed that people who live in an area near
	17	sprayed near areas that are air-sprayed with a
	18	glyphosate formulation had greater DNA damage by the
	19	common assay, I believe, than people who lived further
16:26:04	20	away.
	21	Q. And when they looked at a similar group of
	22	people in 2011 strike that Cavusoglu did a study in
	23	2011; right?
	24	A. Correct.
16 : 26 : 18	25	Q. That wasn't the same people, was it?

	1	A. No, it was not.
	2	Q. But they looked at people who lived in villages
	3	who had been sprayed versus people who lived in villages
	4	that had not been sprayed; right?
16:26:30	5	A. That is correct.
	6	Q. But they waited two years after the last
	7	spraying; is that right?
	8	A. It was a considerable time, and they used a
	9	different assay.
16:26:38	10	Q. And if you wait two years to test for genetic
	11	damage, they didn't see any difference between people who
	12	were sprayed and people who didn't?
	13	A. That's correct.
	14	Q. Is that what you would expect to see?
16:26:49	15	A. If there was no additional exposure in that
	16	two-year period, even if some other component's highly
	17	genotoxicity, you wouldn't expect to see it.
	18	Q. Now, let's talk about Bolognesi.
	19	A. Okay.
16:27:02	20	Q. Do you recall opposing counsel showed some
	21	portions where they stated they didn't think it was a
	22	a long-term effect. Did you see that? Do you remember
	23	that?
	24	A. Yes.
16:27:11	25	Q. What did the Bolognesi study data actually show?


	1	A. Well, I'd really love to get to my notes, but
	2	I'll give you a general. The Bolognesi study was four
	3	cities that where there was exposure in one city
	4	organic farming area, where there was no exposure. They
16:27:34	5	showed that five days after exposure compared to before
	6	exposure, three of the four cities saw a significant
	7	increase in the amount of DNA damage, and then they went
	8	at four months, give or take, and then another one for
	9	some of the cities much later, and, of course, it was
16:27:56	10	going down with time.
	11	Q. And is that, again, consistent with your
	12	understanding of the genotoxicity of glyphosate?
	13	A. It's my understanding of the genotoxicity of
	14	anything. If there's a point of exposure and you follow
16:28:10	15	time, it's going to it's going to decrease.
	16	Q. For purposes of understanding genotoxicity for
	17	people who are chronologically exposed, what's the most
	18	importance data to be looking at here?
	19	A. The five days after exposure.
16:28:25	20	Q. Why is that?
	21	A. Because if they're constantly re-exposed, it
	22	will just be in that same range or maybe even a little
	23	over time.
	24	Q. Okay. Doctor, there was a discussion about
16:28:37	25	something called the Ghisi paper. Do you recall that?


	1	A. Yes, I do.
	2	Q. And are you familiar with that paper?
	3	A. Yes, I am.
	4	MR. WISNER: Okay. Permission to publish, your
16:28:44	5	Honor?
	6	THE COURT: Any objection?
	7	MR. GRIFFIS: No objection, your Honor.
	8	THE COURT: And Mr. Wisner, you do need to start
	9	wrapping up for today.
16:28:52	10	MR. WISNER: I know. I'm just going to get
	11	through this, and then we can stop, and then he'll come
	12	in tomorrow morning, and we'll be out of here right away.
	13	THE COURT: Okay.
	14	Q. BY MR. WISNER: All right. Doctor, on the
16:29:04	15	screen look at that. It works you have a copy of
	16	the Ghisi paper.
	17	Do you see that?
	18	A. Yes, I do.
	19	Q. And we won't belabor this, but you were asked
16:29:12	20	some questions about things in here. Do you recall?
	21	A. Yes.
	22	Q. And there was if we go into it, we see these
	23	different tests, and then here's the the big meta
	24	chart.
16:29:23	25	Do you see that?


	1	A. Yes, I do.
	2	Q. And again, here's the the grand mean right up
	3	here (indicating).
	4	A. Yes.
16:29:31	5	Q. Okay. And now if we go to the next page, there
	6	was a discussion of type of exposures. Let me see if I
	7	can pull it up here. Do you remember this?
	8	A. Yes, I do.
	9	Q. And it turns out that the spraying study, that
16:29:44	10	related primarily to spraying on crocodiles?
	11	A. Yes, it did.
	12	Q. Okay. But there's also topical exposures here.
	13	Do you see that?
	14	A. Yes, I do.
16:29:54	15	Q. Immersions as well?
	16	A. Yes.
	17	Q. Did Mr. Griffis ask you about those at all?
	18	A. No, he did not.
	19	Q. All right. Let's look at when they break it
16:30:04	20	down by animals. This is Chart B.
	21	Do you see that, Doctor?
	22	A. Yes, I do.
	23	Q. And what do we see as it relates to mammals
	24	versus non-mammals?
16:30:13	25	A. Mammals have a much larger effect.


	1	O And anogodilog one thege memola on
	1	Q. And crocodiles, are these mammals or
	2	non-mammals?
	3	A. They're non-mammals.
	4	Q. Okay. So what would be in the mammal section?
16:30:24	5	A. Rats, mouse, cows.
	6	Q. Okay. And then we also have on the next
	7	page, actually, I thought this was interesting. I didn't
	8	show it to you before, but I'm going to show it to you
	9	now. This is a chart as it relates to Roundup and
16:30:43	10	glyphosate.
	11	Do you see that?
	12	A. Yes, I see that.
	13	Q. And this is showing mononuclei in cells after
	14	exposure; right?
16:30:50	15	A. Oh, I'd have to see the legend.
	16	Q. Oh, sorry.
	17	MR. WISNER: We're almost done, your Honor, two
	18	minutes.
	19	THE WITNESS: I think it's micronuclei, but yes.
16:31:08	20	Q. BY MR. WISNER: I'm sorry. Did I say something
	21	different?
	22	Okay. But in any event, Doctor, what does this
	23	chart show?
	24	
		A. That Roundup appears to be more effective than
16:31:18	25	glyphosate over the broad spectrum of species and animals


	1	use.
	2	Q. And the data you've seen as it relates to
	3	Roundup, has that additional effect that you've seen on
	4	genetic damage, is it explained by cytotoxicity?
16:31:36	5	A. I I wouldn't know. I'd have to look at each
	6	study carefully, but I doubt if it's all explained by
	7	cytotoxicity.
	8	Q. In your reviewing of it, you looked for it;
	9	right?
16:31:47	10	A. Yes. Although in animal studies, where most of
	11	this comes from, it's much more difficult to review that.
	12	Unless they tell you something about significant survival
	13	differences, you really can't tell. Certainly in the <i>in</i>
	14	vitro studies, you have to look for that.
16:32:01	15	Q. One last question and then we can end for the
	16	day.
	17	In the human studies, real people actually
	18	sprayed with this stuff in Columbia and Ecuador, that
	19	wasn't cytotoxicity, was it?
16:32:15	20	A. Probably not.
	21	Q. Because that's real-world exposures on
	22	real-world people?
	23	A. Correct.
	24	MR. WISNER: We can end for the day, your Honor.
16:32:23	25	THE COURT: All right. Ladies and Gentlemen,

















1	REPORTER'S CERTIFICATE		
2			
3	I certify that the proceedings in the		
4	within-titled cause were taken at the time and place		
5	herein named; that the proceedings were reported by		
6	me, a duly Certified Shorthand Reporter of the State of		
7	California authorized to administer oaths and		
8	affirmations, and said proceedings were thereafter		
9	transcribed into typewriting.		
10	I further certify that I am not of counsel or		
11	Attorney for either or any of the parties to said		
12	Proceedings, not in any way interested in the outcome of		
13	the cause named in said proceedings.		
14	IN WITNESS WHEREOF, I have hereunto set my hand:		
15	July 16th, 2018.		
16			
17			
18			
19	<%signature%> Leslie Rockwood Rosas		
20	Certified Shorthand Reporter State of California		
21	Certificate No. 3462		
22			
23			
24			
25			